<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Robert Duggan (venture capitalist)</title><meta name="description" content="Robert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and healthcare. He gained prominence as CEO of Pharmacyclics, Inc., where he invested personal funds to revive the struggling firm and oversaw the development of ibrutinib (Imbruvica), a breakthrough treatment for blood cancers that drove the company&#x27;s $21 billion acquisition by AbbVie in 2015, yielding Duggan over $3.5 billion personally. Previously, Duggan chaired Computer Motion from 1990..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Bob Duggan"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Robert_Duggan_(venture_capitalist)"/><meta property="og:title" content="Robert Duggan (venture capitalist)"/><meta property="og:description" content="Robert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and healthcare. He gained prominence as CEO of Pharmacyclics, Inc., where he invested personal funds to revive the struggling firm and oversaw the development of ibrutinib (Imbruvica), a breakthrough treatment for blood cancers that drove the company&#x27;s $21 billion acquisition by AbbVie in 2015, yielding Duggan over $3.5 billion personally. Previously, Duggan chaired Computer Motion from 1990..."/><meta property="og:url" content="https://grokipedia.com/page/Robert_Duggan_(venture_capitalist)"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Robert Duggan (venture capitalist)"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:44.819Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Robert Duggan (venture capitalist)"/><meta name="twitter:description" content="Robert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and healthcare. He gained prominence as CEO of Pharmacyclics, Inc., where he invested personal funds to revive the struggling firm and oversaw the development of ibrutinib (Imbruvica), a breakthrough treatment for blood cancers that drove the company&#x27;s $21 billion acquisition by AbbVie in 2015, yielding Duggan over $3.5 billion personally. Previously, Duggan chaired Computer Motion from 1990..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="82e233bd030b97924a5ddf971be3a0a5-d604b79c0b90dab6-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=82e233bd030b97924a5ddf971be3a0a5,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.4946583728883076,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#robert-duggan-venture-capitalist" class="transition-opacity hover:opacity-100 opacity-50">Robert Duggan (venture capitalist)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#early-life-and-background" class="transition-opacity hover:opacity-100 opacity-50">Early Life and Background</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#childhood-and-upbringing" class="transition-opacity hover:opacity-100 opacity-50">Childhood and Upbringing</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#education-and-early-interests" class="transition-opacity hover:opacity-100 opacity-50">Education and Early Interests</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#entrepreneurial-career" class="transition-opacity hover:opacity-100 opacity-50">Entrepreneurial Career</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#early-business-ventures" class="transition-opacity hover:opacity-100 opacity-50">Early Business Ventures</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#technology-and-robotics-innovations" class="transition-opacity hover:opacity-100 opacity-50">Technology and Robotics Innovations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#biotechnology-leadership" class="transition-opacity hover:opacity-100 opacity-50">Biotechnology Leadership</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#current-and-ongoing-investments" class="transition-opacity hover:opacity-100 opacity-50">Current and Ongoing Investments</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#investment-philosophy-and-duggan-investments" class="transition-opacity hover:opacity-100 opacity-50">Investment Philosophy and Duggan Investments</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#approach-to-venture-capital" class="transition-opacity hover:opacity-100 opacity-50">Approach to Venture Capital</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#key-portfolio-holdings" class="transition-opacity hover:opacity-100 opacity-50">Key Portfolio Holdings</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#scientology-involvement" class="transition-opacity hover:opacity-100 opacity-50">Scientology Involvement</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#long-term-membership-and-contributions" class="transition-opacity hover:opacity-100 opacity-50">Long-Term Membership and Contributions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#influence-on-business-and-philanthropy" class="transition-opacity hover:opacity-100 opacity-50">Influence on Business and Philanthropy</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#philanthropy" class="transition-opacity hover:opacity-100 opacity-50">Philanthropy</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#support-for-education-and-science" class="transition-opacity hover:opacity-100 opacity-50">Support for Education and Science</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#foundation-activities" class="transition-opacity hover:opacity-100 opacity-50">Foundation Activities</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#political-engagement" class="transition-opacity hover:opacity-100 opacity-50">Political Engagement</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#advocacy-for-free-market-policies" class="transition-opacity hover:opacity-100 opacity-50">Advocacy for Free-Market Policies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#financial-support-for-conservative-candidates" class="transition-opacity hover:opacity-100 opacity-50">Financial Support for Conservative Candidates</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#controversies-and-criticisms" class="transition-opacity hover:opacity-100 opacity-50">Controversies and Criticisms</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#corporate-governance-disputes" class="transition-opacity hover:opacity-100 opacity-50">Corporate Governance Disputes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#public-scrutiny-of-religious-ties" class="transition-opacity hover:opacity-100 opacity-50">Public Scrutiny of Religious Ties</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#personal-life" class="transition-opacity hover:opacity-100 opacity-50">Personal Life</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#family-dynamics" class="transition-opacity hover:opacity-100 opacity-50">Family Dynamics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#lifestyle-and-personal-habits" class="transition-opacity hover:opacity-100 opacity-50">Lifestyle and Personal Habits</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#wealth-accumulation-and-recognition" class="transition-opacity hover:opacity-100 opacity-50">Wealth Accumulation and Recognition</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#net-worth-milestones" class="transition-opacity hover:opacity-100 opacity-50">Net Worth Milestones</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#awards-and-industry-acknowledgments" class="transition-opacity hover:opacity-100 opacity-50">Awards and Industry Acknowledgments</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="robert-duggan-venture-capitalist" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Robert Duggan (venture capitalist)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
Robert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and healthcare.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_80qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> He gained prominence as CEO of Pharmacyclics, Inc., where he invested personal funds to revive the struggling firm and oversaw the development of ibrutinib (Imbruvica), a breakthrough treatment for blood cancers that drove the company&#x27;s $21 billion acquisition by AbbVie in 2015, yielding Duggan over $3.5 billion personally.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Previously, Duggan chaired Computer Motion from 1990 to 2003, advancing robotic surgery technology, and pursued investments across robotics, baking, and other industries to build his fortune.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> As CEO of Duggan Investments since 2015, he directs ventures toward innovative, patient-oriented solutions for complex diseases, including a $63 million stake in Summit Therapeutics in 2020, where he serves as co-CEO developing targeted oncology therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_100qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<h2 id="early-life-and-background" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Early Life and Background<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="childhood-and-upbringing" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Childhood and Upbringing<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Robert Duggan was born in 1944 in Oakland, California, as the third of five children in a lower-middle-class family.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">His father, an Irish immigrant who had fled poverty, worked as an industrial engineer for Westinghouse, while his mother, a University of Nebraska graduate, was a registered nurse who also held a job at a local cannery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The family relocated to San Jose in the Silicon Valley region, where they lived in a modest $8,000 home next to a cherry orchard, frequently facing financial strains that required scrimping to cover monthly bills.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_63abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan later recalled his upbringing as one marked by persistent money shortages, with the family &quot;always short of money,&quot; which instilled in him an early appreciation for diligence and resourcefulness from his parents&#x27; example.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_63qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h3 id="education-and-early-interests" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Education and Early Interests<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan graduated <em>cum laude</em> from St. Francis High School in Mountain View, California, in 1966.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Following high school, he enrolled at the University of California, Santa Barbara (UCSB), where he began coursework immediately after graduation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> He later transferred to the University of California, Los Angeles (UCLA), but did not complete a bachelor&#x27;s degree at either university.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">At UCSB, Duggan&#x27;s interest in finance emerged during a corporate finance class, sparking a lifelong enthusiasm for investing that predated his formal business career by decades.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> As a student in the mid-1960s, he initiated early investment activities, laying the groundwork for his venture capital pursuits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> This period also reflected influences from his family&#x27;s emphasis on hard work, instilled by his father&#x27;s engineering discipline and his mother&#x27;s nursing background.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h2 id="entrepreneurial-career" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Entrepreneurial Career<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="early-business-ventures" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Early Business Ventures<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan entered the business world in 1971 by investing $100,000 for a 50% stake in Sunset Designs, a company founded by his fraternity brother Tom Cundith that produced children&#x27;s embroidery kits known as &quot;Jiffy Stitchery Kits.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The venture expanded through manufacturing stitchery and needlepoint products, with Duggan serving as an investor and board member; his initial outlay grew to approximately $14-15 million upon sale to Reckitt &amp; Colman (later Reckitt Benckiser).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 1976, Duggan co-founded Paradise Bakery (initially called Cookie Muncher&#x27;s Paradise) in Long Beach, California, partnering with his then-brother-in-law Dan Patterson, Carter Holmes, and brothers including Mark Patterson.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_67abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> The bakery specialized in fresh-baked cookies, including the &quot;Chocolate Chip Chipper,&quot; and secured contracts to supply products to clients such as McDonald&#x27;s, Disney World, and KFC.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Starting with one location, it expanded to 16-70 outlets across multiple states before its acquisition in 1987, yielding Duggan a 596% absolute return and contributing to the eventual integration into Panera Bread.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By the mid-1980s, Duggan invested in Government Technology Services Inc. (GTSI), a firm providing computer services to the U.S. government, growing its annual revenue from $8 million to $600 million over seven years through an 85% compound annual growth rate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> The company achieved an initial public offering, expanded to 450 employees across 11 offices, and later formed a $740 million entity via acquisition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> These ventures demonstrated Duggan&#x27;s approach to scaling consumer and service-oriented businesses prior to his shift toward technology investments.</span>
<h3 id="technology-and-robotics-innovations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Technology and Robotics Innovations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan served as chairman and chief executive officer of Computer Motion, Inc., one of the pioneering companies in robotic-assisted surgery systems, from the late 1990s until its merger with Intuitive Surgical in 2003.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Computer Motion developed the ZEUS Robotic Surgical System, which enabled remote telesurgery by allowing surgeons to control instruments via a master console connected to robotic arms, marking an early advancement in minimally invasive procedures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> The company also introduced the AESOP system, the first FDA-cleared voice-controlled robotic endoscope positioner, which improved precision in laparoscopic surgeries by reducing surgeon fatigue and tremor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Under Duggan&#x27;s leadership, Computer Motion achieved key milestones, including the first transatlantic telesurgery in 2001, where a surgeon in New York performed a cholecystectomy on a patient in Strasbourg, France, using the ZEUS system over a high-speed fiber-optic connection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> This demonstration highlighted the potential for robotics to extend surgical expertise across distances, though it relied on latency-minimizing technologies and faced challenges like signal reliability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> The merger with Intuitive Surgical combined Computer Motion&#x27;s technologies with the da Vinci Surgical System, creating a dominant player in the field and leading to widespread adoption of robotic-assisted procedures, with Intuitive Surgical reporting over 10 million surgeries performed globally by 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan&#x27;s investments extended to other technology ventures, including Communication Machinery Corp., which focused on data transmission hardware, though these were less centered on robotics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> His approach emphasized hands-on operational involvement in scaling hardware innovations, contributing to Computer Motion&#x27;s growth from a startup to a publicly traded entity before the acquisition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> Subsequent holdings like Pulse Biosciences, where Duggan has been chairman since 2017, incorporate advanced electroporation technologies for non-thermal tissue treatment but diverge from pure robotics into electroceuticals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h3 id="biotechnology-leadership" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Biotechnology Leadership<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 2008, Robert Duggan assumed the roles of Chairman and CEO of Pharmacyclics, Inc., becoming its largest investor and steering the biopharmaceutical company toward the development of ibrutinib, later marketed as Imbruvica.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Under his leadership, Pharmacyclics licensed ibrutinib from Celera Corporation and entered a collaboration with Janssen Biotech (a Johnson &amp; Johnson subsidiary) in 2009, providing up to $150 million in upfront and milestone payments to advance the BTK inhibitor through clinical trials for hematologic malignancies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> The drug received FDA accelerated approval in November 2013 for relapsed or refractory mantle cell lymphoma, followed by full approval for chronic lymphocytic leukemia in combination with rituximab in 2014, demonstrating significant progression-free survival benefits in phase III trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Duggan&#x27;s oversight culminated in AbbVie&#x27;s $21 billion acquisition of Pharmacyclics in May 2015, yielding substantial returns and enabling Imbruvica&#x27;s expanded indications, which by 2023 included multiple B-cell malignancies with annual sales exceeding $10 billion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan&#x27;s biotechnology efforts extended to Summit Therapeutics, where he invested $63 million in February 2020 and joined as Co-CEO, focusing on ivonescimab, a bispecific antibody targeting PD-1 and VEGF for non-small cell lung cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In this role, he directed the company&#x27;s pivot from earlier antibiotic programs to oncology, securing an exclusive license for ivonescimab from Akeso, Inc., in 2022 with potential milestone payments up to $5 billion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Phase III trial results announced on September 9, 2024, indicated ivonescimab reduced the risk of disease progression or death by 49% compared to Merck&#x27;s Keytruda (pembrolizumab) monotherapy in PD-L1-positive patients, marking a potential breakthrough in first-line treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Duggan emphasized a patient-centric model, prioritizing breakthrough therapies through rigorous scientific validation and operational efficiency, as evidenced by Summit&#x27;s streamlined development pipeline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Through Duggan Investments, founded in 2015, he has channeled resources into bioscience ventures, applying lessons from Pharmacyclics to support early-stage biotech firms targeting complex diseases, though direct leadership remains concentrated in entities like Summit.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> His approach, informed by prior successes without formal scientific training, relies on assembling expert teams and fostering innovation grounded in clinical data rather than speculative hypotheses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<h3 id="current-and-ongoing-investments" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Current and Ongoing Investments<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan serves as the founder and chief executive officer of Duggan Investments, a venture capital and equity investment firm established in 2015 that primarily targets patient-centric innovations in biosciences, including cancer therapies, antimicrobial technologies, anti-aging interventions, and stem cell applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> The firm&#x27;s approach emphasizes hands-on involvement in breakthrough solutions for complex diseases, drawing from Duggan&#x27;s prior success in scaling Pharmacyclics from near-insolvency to a $21 billion acquisition by AbbVie in 2015.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> As of late 2024, Duggan Investments maintains significant positions in public equities, with reported holdings exceeding $855 million concentrated in healthcare sectors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ecqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A cornerstone of Duggan&#x27;s ongoing investments is his role as co-chief executive officer and majority shareholder of Summit Therapeutics Inc., a biotechnology company developing targeted oncology treatments. Duggan invested $63 million in Summit in 2020, subsequently assuming co-CEO responsibilities to steer its pipeline, which includes ivonescimab for lung cancer in collaboration with Akeso Inc.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> By September 2025, he held approximately 75.38% of the company&#x27;s shares, totaling over 556 million shares valued at around $179 million based on recent filings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_adabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> This stake underscores Duggan&#x27;s commitment to extending patient lifespans through precision medicine, with Summit&#x27;s market capitalization reflecting advancements in its clinical programs as of October 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_edabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan also chairs the board of directors and holds a controlling interest in Pulse Biosciences Inc., a medical technology firm pioneering Nano-Second Pulsed Field Ablation (nsPFA) for minimally invasive therapies in cardiology, oncology, and dermatology. He joined the board in November 2017 and has directed the company&#x27;s focus on nsPFA&#x27;s potential to ablate cardiac tissue with reduced damage compared to thermal methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> As of December 2024, Duggan owned 43.3 million shares, representing about 79% ownership per the 2025 proxy statement, positioning Pulse as a key vehicle for his bioscience innovation strategy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_adqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond these core holdings, Duggan Investments has pursued selective ventures in related areas, such as a 2022 investment in Subskribe, a subscription management software firm, though this diverges from the primary biosciences emphasis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Earlier interests in companies like CASI Pharmaceuticals and Genoscience Pharma align with oncology and pharma development but lack recent public confirmation of active involvement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Duggan&#x27;s 13F filings as of mid-2025 confirm Summit and Pulse as dominant positions, reflecting a concentrated strategy on high-impact healthcare technologies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<h2 id="investment-philosophy-and-duggan-investments" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Investment Philosophy and Duggan Investments<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="approach-to-venture-capital" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Approach to Venture Capital<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan&#x27;s investment philosophy centers on creating value through collaborative efforts that benefit stakeholders, patients, and society, encapsulated in his principle of working &quot;for the betterment of all involved.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> Through Duggan Investments, founded as a private venture capital and equity firm, he prioritizes sectors like biotechnology and healthcare, targeting companies developing breakthrough, patient-centric solutions to unmet medical needs, such as oncology treatments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> This focus stems from early mentorship under Herbert C. Kay, where Duggan honed a hands-on approach during a three-year apprenticeship, emphasizing curiosity, tenacity, and alignment with innovative teams.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">His strategy involves identifying undervalued or distressed assets with high-upside potential, committing substantial personal capital to secure significant equity stakesâ€”often 50% or moreâ€”and assuming operational leadership roles to drive turnarounds.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> Duggan favors concentrated, high-conviction bets over diversification, sustaining investments through clinical and market risks in biotech, as evidenced by prolonged funding of promising drug candidates despite setbacks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> This risk-tolerant method contrasts with more conservative venture approaches, relying on deep conviction in scientific data and team execution to achieve market dominance, such as over 80% share in targeted therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_egabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan&#x27;s engagements often extend beyond capital provision to strategic oversight, including board seats and CEO positions, fostering environments for rapid scaling and innovation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> He applies first-hand lessons from diverse venturesâ€”spanning consumer goods to roboticsâ€”to biotech, pivoting as needed while maintaining long-term devotion to goals that yield transformative outcomes, though not without the inherent failures common to high-stakes drug development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h3 id="key-portfolio-holdings" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Key Portfolio Holdings<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan Investments maintains a focused portfolio in biotechnology, emphasizing patient-centric innovations in oncology, antimicrobial therapeutics, longevity, anti-aging, and stem cell applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A cornerstone holding is <strong>Summit Therapeutics (NASDAQ: SMMT)</strong>, where Duggan invested $63 million in February 2020 and assumed the role of co-chief executive officer. The company develops ivonescimab, a bispecific antibody targeting PD-1 and VEGF for non-small cell lung cancer, with Phase III trial results announced in May 2024 showing a 48% reduction in disease progression risk compared to pembrolizumab alone. As of October 2025, Duggan beneficially owns over 20% of Summit&#x27;s shares through ongoing purchases, including 26,680 shares acquired on October 21, 2025, for approximately $500,000.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Pulse Biosciences (NASDAQ: PLSE)</strong> represents another major position, with Duggan serving as chairman of the board and controlling about 69% of outstanding shares as of December 13, 2024, valued at roughly $753 million. The firm advances Nano-Pulse Stimulation technology for irreversible electroporation in dermatology, oncology, and cardiology, including the CellFX System cleared by the FDA in 2022 for skin lesion treatments. Duggan&#x27;s ownership stems from strategic investments post-Pharmacyclics exit, underscoring his commitment to non-thermal, tissue-sparing medical devices.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other notable investments include <strong>Genoscience Pharma</strong>, a Phase II clinical-stage company developing GNS561 compounds for liver cancer and neurodegenerative disorders, with Duggan&#x27;s involvement dating to January 2016; and <strong>CASI Pharmaceuticals (NASDAQ: CASI)</strong>, an oncology-focused firm advancing targeted therapies like CID-103 for acute myeloid leukemia, following Duggan&#x27;s investment in March 2018. These align with Duggan&#x27;s biosciences mandate but are smaller relative to Summit and Pulse in terms of ownership and operational influence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h2 id="scientology-involvement" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Scientology Involvement<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="long-term-membership-and-contributions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Long-Term Membership and Contributions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Robert Duggan has been a member of the Church of Scientology for over four decades, with his dedication spanning from at least the late 1970s through at least 2019.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> In a 2019 interview, Duggan confirmed his ongoing commitment to the organization, dispelling speculation among observers that he had departed after years of involvement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan is recognized as the Church of Scientology&#x27;s largest financial supporter, having donated nearly $360 million over his lifetime as of reports in the early 2010s, a figure he stated in 2019 had since been surpassed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> These contributions have primarily funded church missions, building projects, and operational expansions, including recognition of family donations exceeding $7.5 million by 2008 for specific initiatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_alabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_clabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Earlier estimates from 2013 placed his giving at over $20 million, underscoring the scale of his support relative to other donors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_glabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></span>
<h3 id="influence-on-business-and-philanthropy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Influence on Business and Philanthropy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan has attributed much of his entrepreneurial success and personal development to the principles and courses of the Church of Scientology, which he joined in the 1970s. In a 2019 interview, he stated that companies he led or invested in had generated over $100 billion in value, contrasting this with his pre-Scientology efforts, and credited the organization&#x27;s teachings for enabling &quot;the able become more able,&quot; remarking, &quot;For me it worked.&quot; He described daily reading of L. Ron Hubbard&#x27;s writings and applying them across his life, including business decisions, as instrumental in enhancing his capabilities. This perspective aligns with Scientology&#x27;s emphasis on self-improvement through auditing and training, which Duggan said steered him toward becoming &quot;a better and more capable person.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">His business leadership, particularly at Pharmacyclics where he served as CEO from 2008 to 2015 and oversaw the development and commercialization of the cancer drug ibrutinib (Imbruvica), culminating in a $21 billion acquisition by AbbVie in May 2015, reflects a persistent, high-risk investment style that Duggan links to Scientology-influenced resilience and ethical frameworks. While no independent causal analysis verifies this connection, Duggan&#x27;s pattern of injecting personal capitalâ€”such as $50 million into Pharmacyclics during its strugglesâ€”and focusing on transformative biotech ventures post-success at other firms like Telecare echoes Hubbard&#x27;s doctrines on purpose-driven action and overcoming barriers. Subsequent roles, including as executive chairman of Summit Therapeutics since 2020, pursuing antibiotics amid industry challenges, further demonstrate this approach, with Duggan viewing such endeavors as extensions of personal and organizational betterment derived from his faith.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In philanthropy, Scientology has profoundly shaped Duggan&#x27;s giving, positioning the church as the primary recipient of his wealth from business exits. He confirmed donations exceeding $360 millionâ€”reported by Forbes in 2016 and disputed by Duggan as understatedâ€”funding key projects like the Freewinds cruise ship for advanced religious services, the L. Ron Hubbard Hall auditorium in Clearwater, Florida (to which he contributed &quot;deca millions&quot;), and support for church missions worldwide. Duggan framed these contributions as a &quot;personal obligation&quot; to share financial success attained through Scientology, stating, &quot;Thus I feel it is an honor... to share my financial success with Scientology.&quot; This donor status, recognized by the church in 2008 for over $7.5 million from his family at that time, underscores a reciprocal dynamic where business gains directly fuel ecclesiastical expansion, distinct from his broader charitable activities in education and science.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<h2 id="philanthropy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Philanthropy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="support-for-education-and-science" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Support for Education and Science<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan has directed philanthropic support toward his alma mater, the University of California, Santa Barbara (UCSB), including foundational donations to establish the Institute for Energy Efficiency, a research center focused on advancing energy technologies through interdisciplinary scientific collaboration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> He has also funded two faculty chair positions at UCSB to bolster academic expertise in key areas, alongside contributions to athletic programs that indirectly support student development and campus infrastructure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">As a longtime member of UCSB&#x27;s board of trustees since 1989, Duggan has influenced institutional priorities, emphasizing initiatives that align with scientific innovation and educational access, though specific donation amounts for these efforts remain undisclosed in public records.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> His Robert W. Duggan Foundation, established as a 501(c)(3) entity, explicitly includes educational and scientific purposes among its charitable aims, enabling tax-deductible contributions to such causes, but detailed grant allocations prioritize broader humanitarian goals over standalone science funding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">While Duggan&#x27;s overall philanthropy exceeds hundreds of millions of dollars across non-profits, education and science represent a targeted but secondary focus compared to other personal commitments, with no evidence of large-scale endowments to independent scientific research institutions beyond UCSB affiliations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<h3 id="foundation-activities" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Foundation Activities<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The Robert W. Duggan Foundation, established in 2018 as a 501(c)(3) private foundation, operates primarily as a grantmaking entity supporting religious, educational, scientific, and charitable initiatives. Robert W. Duggan serves as its sole trustee and director, contributing approximately 0.25 hours per week without compensation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> The foundation holds net assets of approximately $76.9 million as of December 2023, with revenues of $12.5 million and expenses of $5.93 million in that year, largely directed toward charitable disbursements totaling $5.1 million.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Foundation activities center on disbursing funds to select nonprofits, with no direct program service expenditures reported in IRS Form 990-PF filings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> Grants have emphasized education, including $1.5 million to the UCSB Foundation in 2019 and $500,000 in 2022 for staff scholarships; $100,000 to Stanford University in 2022 for the Robert Duggan Microbiome Fund; and contributions to schools such as $400,000 to Junipero Serra High School in 2022, $90,000 to Riviera Ridge School in 2022, and $50,040 to Manhattan College for scholarships in 2022.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> Health-related support includes $100,000 to the CLL Society in 2023 for chronic lymphocytic leukemia awareness and patient aid. Other disbursements encompass $50,000 to Los Padres Boys Scouts of America in 2019 and a substantial $5 million to the Arias Foundation for Peace and Human Progress in 2023 for Peace Museum development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Religious contributions form a notable portion of grants, such as multiple donations to the Church of Scientology International ($200,000 in 2022, $200,000 in 2020, $50,000 in 2019) and $50,000 to the United States IAS Members&#x27; Trust in 2020.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> These activities reflect a targeted approach, with three grants reported in 2023 and varying numbers in prior years, often prioritizing California-based recipients alongside select international efforts. The foundation maintains no employees and files annually with the IRS, adhering to private foundation distribution requirements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<h2 id="political-engagement" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Political Engagement<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="advocacy-for-free-market-policies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Advocacy for Free-Market Policies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the mid-1990s, Duggan co-founded Metropolis Media with his son Demian to facilitate the transition of formerly communist countries, such as Croatia, Macedonia, Slovenia, and Serbia, toward free-market capitalism by establishing outdoor advertising networks that enabled consumer product promotion in emerging market economies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> The initiative began with a $3 million investment and expanded to over 10,000 billboards in strategic urban locations, allowing approximately 10,000 small businesses to advertise and scale operations previously constrained by central planning.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> As chairman of the board, Duggan secured a seven-figure line of credit from Bank of America, reflecting early financial viability, and the company was later sold to Capital Research for over $45 million before being acquired by the French advertising firm JCDecaux.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ctabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_etabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">This venture exemplified Duggan&#x27;s practical advocacy for free-market principles through infrastructure that fostered competition and consumer-driven growth in post-communist regions, contrasting with state-controlled media environments that had suppressed private enterprise.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> By prioritizing advertising as a tool for economic liberalization, Metropolis Media directly supported the shift from command economies to ones reliant on voluntary exchange and innovation, aligning with Duggan&#x27;s broader entrepreneurial emphasis on enabling market participation for mutual benefit.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h3 id="financial-support-for-conservative-candidates" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Financial Support for Conservative Candidates<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Robert Duggan has directed significant financial resources toward Republican causes, with a focus on supporting Donald Trump&#x27;s 2020 presidential campaign through joint fundraising committees aligned with conservative priorities such as deregulation and free-market policies. In August 2020, Duggan contributed $200,000 to a committee benefiting Trump and the Republican National Committee (RNC).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Between October 15 and November 23, 2020, he donated an additional $617,800 to the Trump Victory joint fundraising committee, which funneled funds to Trump&#x27;s campaign, the RNC, and affiliated state parties.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Overall, Duggan&#x27;s contributions to the Trump Victory Fund totaled $1,638,200 during the 2020 cycle, reflecting his stated intent to increase support as the election approached.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> In the campaign&#x27;s final weeks, he provided another $1 million to the same entity, part of a broader $4.6 million in donations to Trump-aligned groups.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> These efforts positioned Duggan among high-profile biotech investors backing Republican nominees, though public records show limited direct contributions to other individual conservative candidates beyond Trump.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Earlier, on October 4, 2018, Duggan gave $4 million to the Florida Republican Party, a state-level organization that supports GOP candidates emphasizing limited government intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> Federal Election Commission filings confirm these transactions originated from Duggan&#x27;s Clearwater, Florida, address, consistent with his residency and business interests. No verified records indicate substantial support for non-Republican or progressive candidates, aligning his giving with conservative electoral efforts.</span>
<h2 id="controversies-and-criticisms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Controversies and Criticisms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="corporate-governance-disputes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Corporate Governance Disputes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 2015, following the announcement of Pharmacyclics&#x27; $21 billion acquisition by AbbVie, multiple shareholder class action lawsuits were filed against the company&#x27;s board of directors, including CEO and Chairman Robert Duggan, alleging breaches of fiduciary duties in the sale process.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_71abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> The suits, such as <em>Evangelista v. Duggan et al.</em> (filed March 13, 2015, in Santa Clara County Superior Court), claimed the board failed to adequately disclose material information and did not maximize shareholder value amid competing bids from Johnson &amp; Johnson and others.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> The litigation consolidated into <em>In re Pharmacyclics, Inc. Shareholder Litigation</em>, resulting in a disclosure-only settlement in 2016, where additional details on the auction process and financial projections were provided to shareholders without any admission of liability; the court approved the settlement, dismissing the case.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_r1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">More recently, at Summit Therapeutics, where Duggan serves as Chairman and CEO, a lawsuit filed in early 2025 accused him of self-dealing through a $520 million bridge loan arranged in 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> The complaint alleged the loan terms were usurious and timed to exploit a dip in Summit&#x27;s stock price before a licensing deal with Akeso Inc., allowing Duggan and his wife, co-CEO Mahkam Zanganeh, to extract approximately $114 million in personal benefits while the company faced liquidity pressures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> This action highlighted governance concerns over Duggan&#x27;s dominant control, as he and Zanganeh hold significant influence without independent board oversight mitigating conflicts of interest; the case remains ongoing as of October 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Separately, law firms including Pomerantz LLP and Bronstein, Gewirtz &amp; Grossman have launched investigations into Summit for potential securities fraud related to disclosures on clinical trial outcomes and financial maneuvers, potentially implicating board governance failures in transparency and investor protections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_72abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> These probes, initiated in mid-2025, stem from claims that Summit and its executives issued misleading statements, though no formal class actions have been certified to date.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<h3 id="public-scrutiny-of-religious-ties" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Public Scrutiny of Religious Ties<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan has been a longtime member of the Church of Scientology, an organization he joined decades ago and to which he has donated nearly $360 million over his lifetime, making him its largest known contributor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_73abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> These contributions, confirmed by Duggan himself in a 2019 telephone interview with the <em>Tampa Bay Times</em>, occurred alongside his leadership of Pharmacyclics, which sold for $21 billion in 2015.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Public attention to Duggan&#x27;s religious ties intensified following Pharmacyclics&#x27; success with Imbruvica, a cancer drug, positioning him as the world&#x27;s wealthiest Scientologist.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Media profiles, including those in <em>Forbes</em> and <em>STAT News</em>, have highlighted his ongoing practice of Scientology, noting in a 2024 interview that he regularly reads works by founder L. Ron Hubbard.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Speculation arose in 2019 among Scientology observers that Duggan might have disaffiliated after such extensive giving, but he directly refuted this, affirming his dedication.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Scrutiny has centered on potential influences of Scientology on Duggan&#x27;s business practices, with some reports questioning whether principles from the church shaped management at Pharmacyclics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> For instance, Duggan arranged for employees to pursue self-directed programs aimed at developing &quot;24 genius traits,&quot; a concept aligned with Hubbard&#x27;s teachings on personal improvement, raising implicit concerns in biotech commentary about the rationality of such approaches amid high-stakes drug development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> However, Duggan has attributed aspects of his success, including disciplined focus and ethical decision-making, to insights gained from Scientology, without evidence of direct operational interference or regulatory issues stemming from his faith.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> No formal investigations or lawsuits have linked his religious ties to corporate misconduct, though the church&#x27;s broader reputation for aggressive tactics and financial demands has colored perceptions of his philanthropy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></span>
<h2 id="personal-life" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Personal Life<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="family-dynamics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Family Dynamics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Robert Duggan met his future wife, Patricia &quot;Trish&quot; Hagerty, in the 1960s while both were students at the University of California, Santa Barbara, where they became involved in Scientology during the 1970s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> The couple together raised eight children, including six adopted after the death of one son from brain cancer at age 26, an event that profoundly influenced Duggan&#x27;s subsequent focus on oncology investments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Duggans&#x27; family life centered on shared commitments to Scientology, with the couple and their children donating over $7.5 million to the Church of Scientology by 2008, earning recognition for their contributions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> They adopted multiple children, emphasizing family expansion through international adoptions, as Hagerty later reflected on the opportunities available in America for such placements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> The marriage ended in divorce in 2017, after which Duggan maintained involvement in his children&#x27;s lives amid his continued business pursuits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h3 id="lifestyle-and-personal-habits" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Lifestyle and Personal Habits<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Robert Duggan maintains an active outdoor lifestyle centered on surfing, which he has pursued since his youth in Santa Cruz, California. He frequently travels to international surf destinations including Hawaii, Costa Rica, Nicaragua, and Mexico, often incorporating these trips into family activities by teaching his children the sport from as young as age three.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_77abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">At age 80, Duggan continues to surf regularly, viewing each wave as a unique &quot;work of art&quot; that mirrors life&#x27;s challenges and opportunities. He owns a vacation home on the west coast of Costa Rica, where he engages in surfing and other outdoor pursuits such as mountain biking.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_77qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan&#x27;s habits reflect a commitment to physical fitness and adventure, extending beyond surfing to include past achievements like completing the Palo Alto Marathon in 2 hours and 49 minutes. His approach emphasizes resilience and learning from experiences, akin to navigating ocean waves.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<h2 id="wealth-accumulation-and-recognition" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Wealth Accumulation and Recognition<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="net-worth-milestones" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Net Worth Milestones<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan achieved billionaire status in 2013 through the commercial success of Imbruvica (ibrutinib), Pharmacyclics&#x27; FDA-approved treatment for chronic lymphocytic leukemia, which drove substantial appreciation in the company&#x27;s stock and his ownership stake exceeding 20%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The most significant early wealth milestone occurred on May 21, 2015, when AbbVie completed its $21 billion acquisition of Pharmacyclics at $261.25 per share, yielding Duggan approximately $3.5 billion as the largest shareholder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> This transaction marked one of the largest individual payouts from a public company buyout in biotech history, elevating his net worth to around $3 billion at the time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_baabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan&#x27;s subsequent net worth growth stemmed from venture investments, particularly his role as co-CEO and major stakeholder in Summit Therapeutics. The company&#x27;s shares rose over 1,100% in 2024 following positive phase 3 trial data for ivonescimab, a PD-1/VEGF bispecific antibody in collaboration with Akeso, tripling Duggan&#x27;s fortune to approximately $16 billion by September 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>

























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Year</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Event</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Wealth Impact</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2013</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Imbruvica FDA approval and sales ramp-up</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Entered Forbes billionaire list; stake value surges with Pharmacyclics market cap exceeding $10 billion</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bdbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2015</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Pharmacyclics acquisition by AbbVie</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">$3.5 billion personal proceeds; net worth ~$3 billion post-sale</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_blbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_flbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2024</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Summit Therapeutics stock surge on ivonescimab data</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Net worth triples to ~$16 billion from holdings</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_btbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ftbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></td></tr></tbody></table></div>
<h3 id="awards-and-industry-acknowledgments" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Awards and Industry Acknowledgments<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 1985, Robert Duggan received the United States Congressional Medal of Merit from Texas Congressman Ron Paul, recognizing his early contributions to venture investing and technology development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2000, French President Jacques Chirac awarded Duggan the Knight of the Legion of Honor for his leadership in advancing robotic surgical technology as CEO of Computer Motion, Inc., which facilitated innovations in minimally invasive procedures prior to its acquisition by Intuitive Surgical.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Duggan was nominated as a finalist for the Ernst &amp; Young Entrepreneur of the Year Award in Northern California in 2012, in acknowledgment of his role in revitalizing Pharmacyclics, Inc., where he served as CEO and chairman during a period of significant revenue growth exceeding 61% year-over-year among nominees.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2016, the University of California, Santa Barbara&#x27;s College of Engineering presented Duggan with the Venky Narayanamurti Entrepreneurial Leadership Award, honoring his visionary investments and executive achievements in biotechnology and medical technology as a UCSB alumnus and philanthropist.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.forbes.com/profile/robert-duggan/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forbes.com/profile/robert-duggan/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forbes.com/profile/robert-duggan/</a></span></div></li><li id="https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp</a></span></div></li><li id="https://www.fiercepharma.com/m-a/abbvie-s-21b-buyout-puts-pharmacyclics-execs-line-for-4b-payoff" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/m-a/abbvie-s-21b-buyout-puts-pharmacyclics-execs-line-for-4b-payoff" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/m-a/abbvie-s-21b-buyout-puts-pharmacyclics-execs-line-for-4b-payoff</a></span></div></li><li id="https://www.statnews.com/2024/09/09/summit-therapeutics-lung-cancer-treatment-keytruda-robert-duggan/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statnews.com/2024/09/09/summit-therapeutics-lung-cancer-treatment-keytruda-robert-duggan/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statnews.com/2024/09/09/summit-therapeutics-lung-cancer-treatment-keytruda-robert-duggan/</a></span></div></li><li id="https://investors.pulsebiosciences.com/board-member/robert-bob-duggan" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investors.pulsebiosciences.com/board-member/robert-bob-duggan" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investors.pulsebiosciences.com/board-member/robert-bob-duggan</a></span></div></li><li id="https://www.smmttx.com/our-company/leadership/bob-duggan-2/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.smmttx.com/our-company/leadership/bob-duggan-2/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.smmttx.com/our-company/leadership/bob-duggan-2/</a></span></div></li><li id="https://mabumbe.com/people/robert-duggan-biography-career-relationships-achievements-facts/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://mabumbe.com/people/robert-duggan-biography-career-relationships-achievements-facts/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://mabumbe.com/people/robert-duggan-biography-career-relationships-achievements-facts/</a></span></div></li><li id="https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/</a></span></div></li><li id="https://www.lmc-clients.com/duggan/beta/about/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.lmc-clients.com/duggan/beta/about/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.lmc-clients.com/duggan/beta/about/</a></span></div></li><li id="https://brooksysociety.com/robert-duggan-biography/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://brooksysociety.com/robert-duggan-biography/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://brooksysociety.com/robert-duggan-biography/</a></span></div></li><li id="https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/</a></span></div></li><li id="https://www.linkedin.com/in/robertwduggan" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.linkedin.com/in/robertwduggan" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.linkedin.com/in/robertwduggan</a></span></div></li><li id="https://www.businessinsider.com/bob-duggan-summit-therapeutics-stock-wealth-billionaires-rich-list-biotech-2024-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.businessinsider.com/bob-duggan-summit-therapeutics-stock-wealth-billionaires-rich-list-biotech-2024-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.businessinsider.com/bob-duggan-summit-therapeutics-stock-wealth-billionaires-rich-list-biotech-2024-9</a></span></div></li><li id="https://www.geniusinc.com/aboutbobduggan" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.geniusinc.com/aboutbobduggan" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.geniusinc.com/aboutbobduggan</a></span></div></li><li id="https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1-1</a></span></div></li><li id="https://www.dugganinvestmentsresearch.com/about-bob-duggan" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dugganinvestmentsresearch.com/about-bob-duggan" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dugganinvestmentsresearch.com/about-bob-duggan</a></span></div></li><li id="https://www.dugganinvestmentsresearch.com/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dugganinvestmentsresearch.com/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dugganinvestmentsresearch.com/</a></span></div></li><li id="https://investors.pulsebiosciences.com/corporate-governance/board-of-directors" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investors.pulsebiosciences.com/corporate-governance/board-of-directors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investors.pulsebiosciences.com/corporate-governance/board-of-directors</a></span></div></li><li id="https://www.smmttx.com/our-company/board-of-directors-2/robert-w-duggan/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.smmttx.com/our-company/board-of-directors-2/robert-w-duggan/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.smmttx.com/our-company/board-of-directors-2/robert-w-duggan/</a></span></div></li><li id="https://www.wsj.com/tech/biotech/how-a-surfer-who-never-finished-college-became-a-biotech-billionaire-c71eb75f" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.wsj.com/tech/biotech/how-a-surfer-who-never-finished-college-became-a-biotech-billionaire-c71eb75f" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.wsj.com/tech/biotech/how-a-surfer-who-never-finished-college-became-a-biotech-billionaire-c71eb75f</a></span></div></li><li id="https://fintel.io/i/duggan-robert-w" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://fintel.io/i/duggan-robert-w" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://fintel.io/i/duggan-robert-w</a></span></div></li><li id="https://www.marketscreener.com/insider/ROBERT-DUGGAN-A0089M/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.marketscreener.com/insider/ROBERT-DUGGAN-A0089M/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.marketscreener.com/insider/ROBERT-DUGGAN-A0089M/</a></span></div></li><li id="https://whalewisdom.com/filer/duggan-robert-w" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://whalewisdom.com/filer/duggan-robert-w" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://whalewisdom.com/filer/duggan-robert-w</a></span></div></li><li id="https://www.gurufocus.com/insider/3472/robert-w-duggan" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gurufocus.com/insider/3472/robert-w-duggan" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gurufocus.com/insider/3472/robert-w-duggan</a></span></div></li><li id="https://pitchbook.com/profiles/investor/110114-11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pitchbook.com/profiles/investor/110114-11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pitchbook.com/profiles/investor/110114-11</a></span></div></li><li id="https://www.axoniccap.com/team/robert-duggan/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.axoniccap.com/team/robert-duggan/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.axoniccap.com/team/robert-duggan/</a></span></div></li><li id="https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1</a></span></div></li><li id="https://www.forbes.com/sites/nathanvardi/2023/01/13/for-blood-and-money-book-excerpt-wayne-rothbaum-pharmacyclics-robert-duggan/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forbes.com/sites/nathanvardi/2023/01/13/for-blood-and-money-book-excerpt-wayne-rothbaum-pharmacyclics-robert-duggan/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forbes.com/sites/nathanvardi/2023/01/13/for-blood-and-money-book-excerpt-wayne-rothbaum-pharmacyclics-robert-duggan/</a></span></div></li><li id="https://www.quiverquant.com/news/Insider%2BPurchase%253A%2BCo-Chief%2BExecutive%2BOfficer%2Bof%2B%2524SMMT%2BBuys%2B26%252C680%2BShares" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.quiverquant.com/news/Insider%2BPurchase%253A%2BCo-Chief%2BExecutive%2BOfficer%2Bof%2B%2524SMMT%2BBuys%2B26%252C680%2BShares" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.quiverquant.com/news/Insider%2BPurchase%253A%2BCo-Chief%2BExecutive%2BOfficer%2Bof%2B%2524SMMT%2BBuys%2B26%252C680%2BShares</a></span></div></li><li id="https://finance.yahoo.com/news/top-key-executive-robert-duggan-124819517.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://finance.yahoo.com/news/top-key-executive-robert-duggan-124819517.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://finance.yahoo.com/news/top-key-executive-robert-duggan-124819517.html</a></span></div></li><li id="https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/</a></span></div></li><li id="https://www.bloomberg.com/news/articles/2013-01-29/scientology-donor-becomes-a-billionaire-with-cancer-drug" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bloomberg.com/news/articles/2013-01-29/scientology-donor-becomes-a-billionaire-with-cancer-drug" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bloomberg.com/news/articles/2013-01-29/scientology-donor-becomes-a-billionaire-with-cancer-drug</a></span></div></li><li id="https://www.sfgate.com/business/article/Robert-Duggan-Scientology-s-biggest-donor-4234071.php" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sfgate.com/business/article/Robert-Duggan-Scientology-s-biggest-donor-4234071.php" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sfgate.com/business/article/Robert-Duggan-Scientology-s-biggest-donor-4234071.php</a></span></div></li><li id="https://www.lmc-clients.com/duggan/beta/philanthropist/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.lmc-clients.com/duggan/beta/philanthropist/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.lmc-clients.com/duggan/beta/philanthropist/</a></span></div></li><li id="https://projects.propublica.org/nonprofits/organizations/822151899" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://projects.propublica.org/nonprofits/organizations/822151899" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://projects.propublica.org/nonprofits/organizations/822151899</a></span></div></li><li id="https://www.grantmakers.io/profiles/v0/822151899-robert-w-duggan-foundation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grantmakers.io/profiles/v0/822151899-robert-w-duggan-foundation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grantmakers.io/profiles/v0/822151899-robert-w-duggan-foundation</a></span></div></li><li id="https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1</a></span></div></li><li id="https://www.forbes.com/sites/michelatindera/2020/12/09/trump-picked-up-six-figure-checks-from-these-billionaires-in-the-days-before-and-after-the-election/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forbes.com/sites/michelatindera/2020/12/09/trump-picked-up-six-figure-checks-from-these-billionaires-in-the-days-before-and-after-the-election/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forbes.com/sites/michelatindera/2020/12/09/trump-picked-up-six-figure-checks-from-these-billionaires-in-the-days-before-and-after-the-election/</a></span></div></li><li id="https://www.commondreams.org/views/2021/01/11/trumps-top-ten-billionaire-enablers" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.commondreams.org/views/2021/01/11/trumps-top-ten-billionaire-enablers" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.commondreams.org/views/2021/01/11/trumps-top-ten-billionaire-enablers</a></span></div></li><li id="https://www.opensecrets.org/donor-lookup/results?name=robert+duggan" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.opensecrets.org/donor-lookup/results?name=robert+duggan" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.opensecrets.org/donor-lookup/results?name=robert+duggan</a></span></div></li><li id="https://www.opensecrets.org/donor-lookup/results?cand=&amp;cycle=&amp;employ=&amp;order=desc&amp;page=2&amp;sort=A&amp;state=FL&amp;zip=&amp;name=duggan" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.opensecrets.org/donor-lookup/results?cand=&amp;cycle=&amp;employ=&amp;order=desc&amp;page=2&amp;sort=A&amp;state=FL&amp;zip=&amp;name=duggan" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.opensecrets.org/donor-lookup/results?cand=&amp;cycle=&amp;employ=&amp;order=desc&amp;page=2&amp;sort=A&amp;state=FL&amp;zip=&amp;name=duggan</a></span></div></li><li id="https://www.pharmacyclicsshareholderlitigation.com/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmacyclicsshareholderlitigation.com/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmacyclicsshareholderlitigation.com/</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/1551152/000104746915002576/a2223854zs-4.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/1551152/000104746915002576/a2223854zs-4.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/1551152/000104746915002576/a2223854zs-4.htm</a></span></div></li><li id="https://www.casemine.com/judgement/us/5e4b97594653d04a457f636d" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.casemine.com/judgement/us/5e4b97594653d04a457f636d" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.casemine.com/judgement/us/5e4b97594653d04a457f636d</a></span></div></li><li id="https://www.pharmacyclicsshareholderlitigation.com/media/486989/v1_pcy_amendednotice_041916_final.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmacyclicsshareholderlitigation.com/media/486989/v1_pcy_amendednotice_041916_final.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmacyclicsshareholderlitigation.com/media/486989/v1_pcy_amendednotice_041916_final.pdf</a></span></div></li><li id="https://www.leagle.com/decision/incaco20200214071" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.leagle.com/decision/incaco20200214071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.leagle.com/decision/incaco20200214071</a></span></div></li><li id="https://news.bloomberglaw.com/esg/summit-ceo-bob-duggan-sued-over-outlandish-self-dealing-loan" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.bloomberglaw.com/esg/summit-ceo-bob-duggan-sued-over-outlandish-self-dealing-loan" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.bloomberglaw.com/esg/summit-ceo-bob-duggan-sued-over-outlandish-self-dealing-loan</a></span></div></li><li id="https://scientologymoneyproject.com/2025/06/05/bob-duggans-pharma-company-summit-therapeutics-targeted-by-powerhouse-securities-law-firm-pomerantz-llp/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://scientologymoneyproject.com/2025/06/05/bob-duggans-pharma-company-summit-therapeutics-targeted-by-powerhouse-securities-law-firm-pomerantz-llp/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://scientologymoneyproject.com/2025/06/05/bob-duggans-pharma-company-summit-therapeutics-targeted-by-powerhouse-securities-law-firm-pomerantz-llp/</a></span></div></li><li id="https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc---smmt-302587123.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc---smmt-302587123.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc---smmt-302587123.html</a></span></div></li><li id="https://www.wjbf.com/business/press-releases/accesswire/1071260/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-summit-therapeutics-inc-smmt-and-encourages-shareholders-to-learn-more-about-the-investigation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.wjbf.com/business/press-releases/accesswire/1071260/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-summit-therapeutics-inc-smmt-and-encourages-shareholders-to-learn-more-about-the-investigation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.wjbf.com/business/press-releases/accesswire/1071260/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-summit-therapeutics-inc-smmt-and-encourages-shareholders-to-learn-more-about-the-investigation</a></span></div></li><li id="https://www.cbs42.com/business/press-releases/accesswire/1087415/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc-smmt" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cbs42.com/business/press-releases/accesswire/1087415/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc-smmt" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cbs42.com/business/press-releases/accesswire/1087415/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc-smmt</a></span></div></li><li id="https://www.forbes.com/sites/leahrosenbaum/2020/10/01/the-scientologist-billionaire-trying-to-make-a-new-antibiotic/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forbes.com/sites/leahrosenbaum/2020/10/01/the-scientologist-billionaire-trying-to-make-a-new-antibiotic/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forbes.com/sites/leahrosenbaum/2020/10/01/the-scientologist-billionaire-trying-to-make-a-new-antibiotic/</a></span></div></li><li id="https://www.science.org/content/blog-post/one-and-done" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/content/blog-post/one-and-done" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/content/blog-post/one-and-done</a></span></div></li><li id="https://www.science.org/content/blog-post/geniuses-pharmacyclics" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/content/blog-post/geniuses-pharmacyclics" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/content/blog-post/geniuses-pharmacyclics</a></span></div></li><li id="https://www.forbes.com/sites/matthewherper/2014/04/16/a-lucky-drug-made-pharmacyclics-robert-duggan-a-billionaire-will-long-term-success-follow/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forbes.com/sites/matthewherper/2014/04/16/a-lucky-drug-made-pharmacyclics-robert-duggan-a-billionaire-will-long-term-success-follow/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forbes.com/sites/matthewherper/2014/04/16/a-lucky-drug-made-pharmacyclics-robert-duggan-a-billionaire-will-long-term-success-follow/</a></span></div></li><li id="https://nonprofitquarterly.org/philanthropy/21801-no-mystery-in-the-why-of-scientology-s-largest-donor.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nonprofitquarterly.org/philanthropy/21801-no-mystery-in-the-why-of-scientology-s-largest-donor.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nonprofitquarterly.org/philanthropy/21801-no-mystery-in-the-why-of-scientology-s-largest-donor.html</a></span></div></li><li id="https://www.imaginemuseum.com/trish-duggan-talks-imagine-museum/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.imaginemuseum.com/trish-duggan-talks-imagine-museum/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.imaginemuseum.com/trish-duggan-talks-imagine-museum/</a></span></div></li><li id="https://tonyortega.org/2014/10/15/a-perplexing-tale-about-bob-duggan-the-richest-scientologist-in-the-world/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://tonyortega.org/2014/10/15/a-perplexing-tale-about-bob-duggan-the-richest-scientologist-in-the-world/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://tonyortega.org/2014/10/15/a-perplexing-tale-about-bob-duggan-the-richest-scientologist-in-the-world/</a></span></div></li><li id="https://www.globenewswire.com/news-release/2012/05/15/1186731/0/en/Ernst-Young-Entrepreneur-Of-The-Year-R-2012-Award-Nominees-in-Northern-California-Experience-61-Percent-Increase-in-Year-Over-Year-Revenue-Growth.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.globenewswire.com/news-release/2012/05/15/1186731/0/en/Ernst-Young-Entrepreneur-Of-The-Year-R-2012-Award-Nominees-in-Northern-California-Experience-61-Percent-Increase-in-Year-Over-Year-Revenue-Growth.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.globenewswire.com/news-release/2012/05/15/1186731/0/en/Ernst-Young-Entrepreneur-Of-The-Year-R-2012-Award-Nominees-in-Northern-California-Experience-61-Percent-Increase-in-Year-Over-Year-Revenue-Growth.html</a></span></div></li><li id="https://engineering.ucsb.edu/news/alum-robert-duggan-receives-narayanamurti-entrepreneurial-leadership-award" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://engineering.ucsb.edu/news/alum-robert-duggan-receives-narayanamurti-entrepreneurial-leadership-award" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://engineering.ucsb.edu/news/alum-robert-duggan-receives-narayanamurti-entrepreneurial-leadership-award</a></span></div></li><li id="https://www.noozhawk.com/ucsb_alum_robert_duggan_receives_2016_venky_narayanamurti_entrepreneurial_l/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.noozhawk.com/ucsb_alum_robert_duggan_receives_2016_venky_narayanamurti_entrepreneurial_l/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.noozhawk.com/ucsb_alum_robert_duggan_receives_2016_venky_narayanamurti_entrepreneurial_l/</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0" id="_R_" async=""></script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Robert_Duggan_(venture_capitalist)\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Robert_Duggan_(venture_capitalist)\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Robert_Duggan_(venture_capitalist)\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:Tc94d,"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"# Robert Duggan (venture capitalist)\n\n![Robert Duggan](./_assets_/Entrepreneur_-_Bob_Duggan.jpg)  \nRobert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and healthcare.[](https://www.forbes.com/profile/robert-duggan/)[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp) He gained prominence as CEO of Pharmacyclics, Inc., where he invested personal funds to revive the struggling firm and oversaw the development of ibrutinib (Imbruvica), a breakthrough treatment for blood cancers that drove the company's $21 billion acquisition by AbbVie in 2015, yielding Duggan over $3.5 billion personally.[](https://www.forbes.com/profile/robert-duggan/)[](https://www.fiercepharma.com/m-a/abbvie-s-21b-buyout-puts-pharmacyclics-execs-line-for-4b-payoff)[](https://www.statnews.com/2024/09/09/summit-therapeutics-lung-cancer-treatment-keytruda-robert-duggan/) Previously, Duggan chaired Computer Motion from 1990 to 2003, advancing robotic surgery technology, and pursued investments across robotics, baking, and other industries to build his fortune.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://investors.pulsebiosciences.com/board-member/robert-bob-duggan) As CEO of Duggan Investments since 2015, he directs ventures toward innovative, patient-oriented solutions for complex diseases, including a $63 million stake in Summit Therapeutics in 2020, where he serves as co-CEO developing targeted oncology therapies.[](https://investors.pulsebiosciences.com/board-member/robert-bob-duggan)[](https://www.forbes.com/profile/robert-duggan/)[](https://www.smmttx.com/our-company/leadership/bob-duggan-2/)\n\n## Early Life and Background\n\n### Childhood and Upbringing\n\nRobert Duggan was born in 1944 in Oakland, California, as the third of five children in a lower-middle-class family.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://mabumbe.com/people/robert-duggan-biography-career-relationships-achievements-facts/)[](https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/)\n\nHis father, an Irish immigrant who had fled poverty, worked as an industrial engineer for Westinghouse, while his mother, a University of Nebraska graduate, was a registered nurse who also held a job at a local cannery.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.lmc-clients.com/duggan/beta/about/)[](https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/)[](https://mabumbe.com/people/robert-duggan-biography-career-relationships-achievements-facts/)\n\nThe family relocated to San Jose in the Silicon Valley region, where they lived in a modest $8,000 home next to a cherry orchard, frequently facing financial strains that required scrimping to cover monthly bills.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.lmc-clients.com/duggan/beta/about/)[](https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/)\n\nDuggan later recalled his upbringing as one marked by persistent money shortages, with the family \"always short of money,\" which instilled in him an early appreciation for diligence and resourcefulness from his parents' example.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.lmc-clients.com/duggan/beta/about/)\n\n### Education and Early Interests\n\nDuggan graduated *cum laude* from St. Francis High School in Mountain View, California, in 1966.[](https://www.lmc-clients.com/duggan/beta/about/) Following high school, he enrolled at the University of California, Santa Barbara (UCSB), where he began coursework immediately after graduation.[](https://brooksysociety.com/robert-duggan-biography/) He later transferred to the University of California, Los Angeles (UCLA), but did not complete a bachelor's degree at either university.[](https://www.forbes.com/profile/robert-duggan/)\n\nAt UCSB, Duggan's interest in finance emerged during a corporate finance class, sparking a lifelong enthusiasm for investing that predated his formal business career by decades.[](https://www.forbes.com/profile/robert-duggan/) As a student in the mid-1960s, he initiated early investment activities, laying the groundwork for his venture capital pursuits.[](https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/) This period also reflected influences from his family's emphasis on hard work, instilled by his father's engineering discipline and his mother's nursing background.[](https://www.lmc-clients.com/duggan/beta/about/)\n\n## Entrepreneurial Career\n\n### Early Business Ventures\n\nDuggan entered the business world in 1971 by investing $100,000 for a 50% stake in Sunset Designs, a company founded by his fraternity brother Tom Cundith that produced children's embroidery kits known as \"Jiffy Stitchery Kits.\"[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp) The venture expanded through manufacturing stitchery and needlepoint products, with Duggan serving as an investor and board member; his initial outlay grew to approximately $14-15 million upon sale to Reckitt \u0026 Colman (later Reckitt Benckiser).[](https://www.lmc-clients.com/duggan/beta/about/)[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)\n\nIn 1976, Duggan co-founded Paradise Bakery (initially called Cookie Muncher's Paradise) in Long Beach, California, partnering with his then-brother-in-law Dan Patterson, Carter Holmes, and brothers including Mark Patterson.[](https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/)[](https://www.linkedin.com/in/robertwduggan) The bakery specialized in fresh-baked cookies, including the \"Chocolate Chip Chipper,\" and secured contracts to supply products to clients such as McDonald's, Disney World, and KFC.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.businessinsider.com/bob-duggan-summit-therapeutics-stock-wealth-billionaires-rich-list-biotech-2024-9) Starting with one location, it expanded to 16-70 outlets across multiple states before its acquisition in 1987, yielding Duggan a 596% absolute return and contributing to the eventual integration into Panera Bread.[](https://www.geniusinc.com/aboutbobduggan)[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)\n\nBy the mid-1980s, Duggan invested in Government Technology Services Inc. (GTSI), a firm providing computer services to the U.S. government, growing its annual revenue from $8 million to $600 million over seven years through an 85% compound annual growth rate.[](https://www.geniusinc.com/aboutbobduggan) The company achieved an initial public offering, expanded to 450 employees across 11 offices, and later formed a $740 million entity via acquisition.[](https://www.geniusinc.com/aboutbobduggan) These ventures demonstrated Duggan's approach to scaling consumer and service-oriented businesses prior to his shift toward technology investments.\n\n### Technology and Robotics Innovations\n\nDuggan served as chairman and chief executive officer of Computer Motion, Inc., one of the pioneering companies in robotic-assisted surgery systems, from the late 1990s until its merger with Intuitive Surgical in 2003.[](https://www.lmc-clients.com/duggan/beta/about/)[](https://www.smmttx.com/our-company/leadership/bob-duggan-2/) Computer Motion developed the ZEUS Robotic Surgical System, which enabled remote telesurgery by allowing surgeons to control instruments via a master console connected to robotic arms, marking an early advancement in minimally invasive procedures.[](https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1-1) The company also introduced the AESOP system, the first FDA-cleared voice-controlled robotic endoscope positioner, which improved precision in laparoscopic surgeries by reducing surgeon fatigue and tremor.[](https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1-1)\n\nUnder Duggan's leadership, Computer Motion achieved key milestones, including the first transatlantic telesurgery in 2001, where a surgeon in New York performed a cholecystectomy on a patient in Strasbourg, France, using the ZEUS system over a high-speed fiber-optic connection.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp) This demonstration highlighted the potential for robotics to extend surgical expertise across distances, though it relied on latency-minimizing technologies and faced challenges like signal reliability.[](https://www.dugganinvestmentsresearch.com/about-bob-duggan) The merger with Intuitive Surgical combined Computer Motion's technologies with the da Vinci Surgical System, creating a dominant player in the field and leading to widespread adoption of robotic-assisted procedures, with Intuitive Surgical reporting over 10 million surgeries performed globally by 2023.[](https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/)\n\nDuggan's investments extended to other technology ventures, including Communication Machinery Corp., which focused on data transmission hardware, though these were less centered on robotics.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp) His approach emphasized hands-on operational involvement in scaling hardware innovations, contributing to Computer Motion's growth from a startup to a publicly traded entity before the acquisition.[](https://www.dugganinvestmentsresearch.com/) Subsequent holdings like Pulse Biosciences, where Duggan has been chairman since 2017, incorporate advanced electroporation technologies for non-thermal tissue treatment but diverge from pure robotics into electroceuticals.[](https://investors.pulsebiosciences.com/corporate-governance/board-of-directors)\n\n### Biotechnology Leadership\n\nIn 2008, Robert Duggan assumed the roles of Chairman and CEO of Pharmacyclics, Inc., becoming its largest investor and steering the biopharmaceutical company toward the development of ibrutinib, later marketed as Imbruvica.[](https://www.smmttx.com/our-company/leadership/bob-duggan-2/) Under his leadership, Pharmacyclics licensed ibrutinib from Celera Corporation and entered a collaboration with Janssen Biotech (a Johnson \u0026 Johnson subsidiary) in 2009, providing up to $150 million in upfront and milestone payments to advance the BTK inhibitor through clinical trials for hematologic malignancies.[](https://www.smmttx.com/our-company/board-of-directors-2/robert-w-duggan/) The drug received FDA accelerated approval in November 2013 for relapsed or refractory mantle cell lymphoma, followed by full approval for chronic lymphocytic leukemia in combination with rituximab in 2014, demonstrating significant progression-free survival benefits in phase III trials.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp) Duggan's oversight culminated in AbbVie's $21 billion acquisition of Pharmacyclics in May 2015, yielding substantial returns and enabling Imbruvica's expanded indications, which by 2023 included multiple B-cell malignancies with annual sales exceeding $10 billion.[](https://www.dugganinvestmentsresearch.com/)\n\nDuggan's biotechnology efforts extended to Summit Therapeutics, where he invested $63 million in February 2020 and joined as Co-CEO, focusing on ivonescimab, a bispecific antibody targeting PD-1 and VEGF for non-small cell lung cancer.[](https://www.forbes.com/profile/robert-duggan/) In this role, he directed the company's pivot from earlier antibiotic programs to oncology, securing an exclusive license for ivonescimab from Akeso, Inc., in 2022 with potential milestone payments up to $5 billion.[](https://www.smmttx.com/our-company/leadership/bob-duggan-2/) Phase III trial results announced on September 9, 2024, indicated ivonescimab reduced the risk of disease progression or death by 49% compared to Merck's Keytruda (pembrolizumab) monotherapy in PD-L1-positive patients, marking a potential breakthrough in first-line treatment.[](https://www.statnews.com/2024/09/09/summit-therapeutics-lung-cancer-treatment-keytruda-robert-duggan/) Duggan emphasized a patient-centric model, prioritizing breakthrough therapies through rigorous scientific validation and operational efficiency, as evidenced by Summit's streamlined development pipeline.[](https://www.smmttx.com/our-company/board-of-directors-2/robert-w-duggan/)\n\nThrough Duggan Investments, founded in 2015, he has channeled resources into bioscience ventures, applying lessons from Pharmacyclics to support early-stage biotech firms targeting complex diseases, though direct leadership remains concentrated in entities like Summit.[](https://www.dugganinvestmentsresearch.com/) His approach, informed by prior successes without formal scientific training, relies on assembling expert teams and fostering innovation grounded in clinical data rather than speculative hypotheses.[](https://www.wsj.com/tech/biotech/how-a-surfer-who-never-finished-college-became-a-biotech-billionaire-c71eb75f)\n\n### Current and Ongoing Investments\n\nDuggan serves as the founder and chief executive officer of Duggan Investments, a venture capital and equity investment firm established in 2015 that primarily targets patient-centric innovations in biosciences, including cancer therapies, antimicrobial technologies, anti-aging interventions, and stem cell applications.[](https://www.dugganinvestmentsresearch.com/)[](https://investors.pulsebiosciences.com/corporate-governance/board-of-directors) The firm's approach emphasizes hands-on involvement in breakthrough solutions for complex diseases, drawing from Duggan's prior success in scaling Pharmacyclics from near-insolvency to a $21 billion acquisition by AbbVie in 2015.[](https://www.dugganinvestmentsresearch.com/) As of late 2024, Duggan Investments maintains significant positions in public equities, with reported holdings exceeding $855 million concentrated in healthcare sectors.[](https://fintel.io/i/duggan-robert-w)\n\nA cornerstone of Duggan's ongoing investments is his role as co-chief executive officer and majority shareholder of Summit Therapeutics Inc., a biotechnology company developing targeted oncology treatments. Duggan invested $63 million in Summit in 2020, subsequently assuming co-CEO responsibilities to steer its pipeline, which includes ivonescimab for lung cancer in collaboration with Akeso Inc.[](https://www.forbes.com/profile/robert-duggan/)[](https://www.smmttx.com/our-company/leadership/bob-duggan-2/) By September 2025, he held approximately 75.38% of the company's shares, totaling over 556 million shares valued at around $179 million based on recent filings.[](https://www.marketscreener.com/insider/ROBERT-DUGGAN-A0089M/) This stake underscores Duggan's commitment to extending patient lifespans through precision medicine, with Summit's market capitalization reflecting advancements in its clinical programs as of October 2025.[](https://whalewisdom.com/filer/duggan-robert-w)\n\nDuggan also chairs the board of directors and holds a controlling interest in Pulse Biosciences Inc., a medical technology firm pioneering Nano-Second Pulsed Field Ablation (nsPFA) for minimally invasive therapies in cardiology, oncology, and dermatology. He joined the board in November 2017 and has directed the company's focus on nsPFA's potential to ablate cardiac tissue with reduced damage compared to thermal methods.[](https://investors.pulsebiosciences.com/corporate-governance/board-of-directors)[](https://investors.pulsebiosciences.com/board-member/robert-bob-duggan) As of December 2024, Duggan owned 43.3 million shares, representing about 79% ownership per the 2025 proxy statement, positioning Pulse as a key vehicle for his bioscience innovation strategy.[](https://www.gurufocus.com/insider/3472/robert-w-duggan)[](https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/)\n\nBeyond these core holdings, Duggan Investments has pursued selective ventures in related areas, such as a 2022 investment in Subskribe, a subscription management software firm, though this diverges from the primary biosciences emphasis.[](https://pitchbook.com/profiles/investor/110114-11) Earlier interests in companies like CASI Pharmaceuticals and Genoscience Pharma align with oncology and pharma development but lack recent public confirmation of active involvement.[](https://pitchbook.com/profiles/investor/110114-11) Duggan's 13F filings as of mid-2025 confirm Summit and Pulse as dominant positions, reflecting a concentrated strategy on high-impact healthcare technologies.[](https://whalewisdom.com/filer/duggan-robert-w)\n\n## Investment Philosophy and Duggan Investments\n\n### Approach to Venture Capital\n\nDuggan's investment philosophy centers on creating value through collaborative efforts that benefit stakeholders, patients, and society, encapsulated in his principle of working \"for the betterment of all involved.\"[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.dugganinvestmentsresearch.com/) Through Duggan Investments, founded as a private venture capital and equity firm, he prioritizes sectors like biotechnology and healthcare, targeting companies developing breakthrough, patient-centric solutions to unmet medical needs, such as oncology treatments.[](https://www.linkedin.com/in/robertwduggan)[](https://www.axoniccap.com/team/robert-duggan/) This focus stems from early mentorship under Herbert C. Kay, where Duggan honed a hands-on approach during a three-year apprenticeship, emphasizing curiosity, tenacity, and alignment with innovative teams.[](https://www.lmc-clients.com/duggan/beta/about/)\n\nHis strategy involves identifying undervalued or distressed assets with high-upside potential, committing substantial personal capital to secure significant equity stakesâ€”often 50% or moreâ€”and assuming operational leadership roles to drive turnarounds.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1) Duggan favors concentrated, high-conviction bets over diversification, sustaining investments through clinical and market risks in biotech, as evidenced by prolonged funding of promising drug candidates despite setbacks.[](https://www.forbes.com/sites/nathanvardi/2023/01/13/for-blood-and-money-book-excerpt-wayne-rothbaum-pharmacyclics-robert-duggan/) This risk-tolerant method contrasts with more conservative venture approaches, relying on deep conviction in scientific data and team execution to achieve market dominance, such as over 80% share in targeted therapies.[](https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1)\n\nDuggan's engagements often extend beyond capital provision to strategic oversight, including board seats and CEO positions, fostering environments for rapid scaling and innovation.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.lmc-clients.com/duggan/beta/about/) He applies first-hand lessons from diverse venturesâ€”spanning consumer goods to roboticsâ€”to biotech, pivoting as needed while maintaining long-term devotion to goals that yield transformative outcomes, though not without the inherent failures common to high-stakes drug development.[](https://www.forbes.com/sites/nathanvardi/2023/01/13/for-blood-and-money-book-excerpt-wayne-rothbaum-pharmacyclics-robert-duggan/)[](https://www.lmc-clients.com/duggan/beta/about/)\n\n### Key Portfolio Holdings\n\nDuggan Investments maintains a focused portfolio in biotechnology, emphasizing patient-centric innovations in oncology, antimicrobial therapeutics, longevity, anti-aging, and stem cell applications.[](https://www.dugganinvestmentsresearch.com/)\n\nA cornerstone holding is **Summit Therapeutics (NASDAQ: SMMT)**, where Duggan invested $63 million in February 2020 and assumed the role of co-chief executive officer. The company develops ivonescimab, a bispecific antibody targeting PD-1 and VEGF for non-small cell lung cancer, with Phase III trial results announced in May 2024 showing a 48% reduction in disease progression risk compared to pembrolizumab alone. As of October 2025, Duggan beneficially owns over 20% of Summit's shares through ongoing purchases, including 26,680 shares acquired on October 21, 2025, for approximately $500,000.[](https://www.forbes.com/profile/robert-duggan/)[](https://www.smmttx.com/our-company/leadership/bob-duggan-2/)[](https://www.quiverquant.com/news/Insider%2BPurchase%253A%2BCo-Chief%2BExecutive%2BOfficer%2Bof%2B%2524SMMT%2BBuys%2B26%252C680%2BShares)[](https://www.gurufocus.com/insider/3472/robert-w-duggan)\n\n**Pulse Biosciences (NASDAQ: PLSE)** represents another major position, with Duggan serving as chairman of the board and controlling about 69% of outstanding shares as of December 13, 2024, valued at roughly $753 million. The firm advances Nano-Pulse Stimulation technology for irreversible electroporation in dermatology, oncology, and cardiology, including the CellFX System cleared by the FDA in 2022 for skin lesion treatments. Duggan's ownership stems from strategic investments post-Pharmacyclics exit, underscoring his commitment to non-thermal, tissue-sparing medical devices.[](https://finance.yahoo.com/news/top-key-executive-robert-duggan-124819517.html)[](https://www.gurufocus.com/insider/3472/robert-w-duggan)[](https://investors.pulsebiosciences.com/board-member/robert-bob-duggan)\n\nOther notable investments include **Genoscience Pharma**, a Phase II clinical-stage company developing GNS561 compounds for liver cancer and neurodegenerative disorders, with Duggan's involvement dating to January 2016; and **CASI Pharmaceuticals (NASDAQ: CASI)**, an oncology-focused firm advancing targeted therapies like CID-103 for acute myeloid leukemia, following Duggan's investment in March 2018. These align with Duggan's biosciences mandate but are smaller relative to Summit and Pulse in terms of ownership and operational influence.[](https://pitchbook.com/profiles/investor/110114-11)\n\n## Scientology Involvement\n\n### Long-Term Membership and Contributions\n\nRobert Duggan has been a member of the Church of Scientology for over four decades, with his dedication spanning from at least the late 1970s through at least 2019.[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/) In a 2019 interview, Duggan confirmed his ongoing commitment to the organization, dispelling speculation among observers that he had departed after years of involvement.[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/)\n\nDuggan is recognized as the Church of Scientology's largest financial supporter, having donated nearly $360 million over his lifetime as of reports in the early 2010s, a figure he stated in 2019 had since been surpassed.[](https://www.forbes.com/profile/robert-duggan/)[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/) These contributions have primarily funded church missions, building projects, and operational expansions, including recognition of family donations exceeding $7.5 million by 2008 for specific initiatives.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.bloomberg.com/news/articles/2013-01-29/scientology-donor-becomes-a-billionaire-with-cancer-drug) Earlier estimates from 2013 placed his giving at over $20 million, underscoring the scale of his support relative to other donors.[](https://www.sfgate.com/business/article/Robert-Duggan-Scientology-s-biggest-donor-4234071.php)\n\n### Influence on Business and Philanthropy\n\nDuggan has attributed much of his entrepreneurial success and personal development to the principles and courses of the Church of Scientology, which he joined in the 1970s. In a 2019 interview, he stated that companies he led or invested in had generated over $100 billion in value, contrasting this with his pre-Scientology efforts, and credited the organization's teachings for enabling \"the able become more able,\" remarking, \"For me it worked.\" He described daily reading of L. Ron Hubbard's writings and applying them across his life, including business decisions, as instrumental in enhancing his capabilities. This perspective aligns with Scientology's emphasis on self-improvement through auditing and training, which Duggan said steered him toward becoming \"a better and more capable person.\"[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/)[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)\n\nHis business leadership, particularly at Pharmacyclics where he served as CEO from 2008 to 2015 and oversaw the development and commercialization of the cancer drug ibrutinib (Imbruvica), culminating in a $21 billion acquisition by AbbVie in May 2015, reflects a persistent, high-risk investment style that Duggan links to Scientology-influenced resilience and ethical frameworks. While no independent causal analysis verifies this connection, Duggan's pattern of injecting personal capitalâ€”such as $50 million into Pharmacyclics during its strugglesâ€”and focusing on transformative biotech ventures post-success at other firms like Telecare echoes Hubbard's doctrines on purpose-driven action and overcoming barriers. Subsequent roles, including as executive chairman of Summit Therapeutics since 2020, pursuing antibiotics amid industry challenges, further demonstrate this approach, with Duggan viewing such endeavors as extensions of personal and organizational betterment derived from his faith.[](https://www.bloomberg.com/news/articles/2013-01-29/scientology-donor-becomes-a-billionaire-with-cancer-drug)[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)\n\nIn philanthropy, Scientology has profoundly shaped Duggan's giving, positioning the church as the primary recipient of his wealth from business exits. He confirmed donations exceeding $360 millionâ€”reported by Forbes in 2016 and disputed by Duggan as understatedâ€”funding key projects like the Freewinds cruise ship for advanced religious services, the L. Ron Hubbard Hall auditorium in Clearwater, Florida (to which he contributed \"deca millions\"), and support for church missions worldwide. Duggan framed these contributions as a \"personal obligation\" to share financial success attained through Scientology, stating, \"Thus I feel it is an honor... to share my financial success with Scientology.\" This donor status, recognized by the church in 2008 for over $7.5 million from his family at that time, underscores a reciprocal dynamic where business gains directly fuel ecclesiastical expansion, distinct from his broader charitable activities in education and science.[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/)[](https://www.sfgate.com/business/article/Robert-Duggan-Scientology-s-biggest-donor-4234071.php)[](https://www.bloomberg.com/news/articles/2013-01-29/scientology-donor-becomes-a-billionaire-with-cancer-drug)\n\n## Philanthropy\n\n### Support for Education and Science\n\nDuggan has directed philanthropic support toward his alma mater, the University of California, Santa Barbara (UCSB), including foundational donations to establish the Institute for Energy Efficiency, a research center focused on advancing energy technologies through interdisciplinary scientific collaboration.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp) He has also funded two faculty chair positions at UCSB to bolster academic expertise in key areas, alongside contributions to athletic programs that indirectly support student development and campus infrastructure.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)\n\nAs a longtime member of UCSB's board of trustees since 1989, Duggan has influenced institutional priorities, emphasizing initiatives that align with scientific innovation and educational access, though specific donation amounts for these efforts remain undisclosed in public records.[](https://www.lmc-clients.com/duggan/beta/philanthropist/) His Robert W. Duggan Foundation, established as a 501(c)(3) entity, explicitly includes educational and scientific purposes among its charitable aims, enabling tax-deductible contributions to such causes, but detailed grant allocations prioritize broader humanitarian goals over standalone science funding.[](https://projects.propublica.org/nonprofits/organizations/822151899)\n\nWhile Duggan's overall philanthropy exceeds hundreds of millions of dollars across non-profits, education and science represent a targeted but secondary focus compared to other personal commitments, with no evidence of large-scale endowments to independent scientific research institutions beyond UCSB affiliations.[](https://www.lmc-clients.com/duggan/beta/philanthropist/)\n\n### Foundation Activities\n\nThe Robert W. Duggan Foundation, established in 2018 as a 501(c)(3) private foundation, operates primarily as a grantmaking entity supporting religious, educational, scientific, and charitable initiatives. Robert W. Duggan serves as its sole trustee and director, contributing approximately 0.25 hours per week without compensation.[](https://www.grantmakers.io/profiles/v0/822151899-robert-w-duggan-foundation) The foundation holds net assets of approximately $76.9 million as of December 2023, with revenues of $12.5 million and expenses of $5.93 million in that year, largely directed toward charitable disbursements totaling $5.1 million.[](https://projects.propublica.org/nonprofits/organizations/822151899)\n\nFoundation activities center on disbursing funds to select nonprofits, with no direct program service expenditures reported in IRS Form 990-PF filings.[](https://projects.propublica.org/nonprofits/organizations/822151899) Grants have emphasized education, including $1.5 million to the UCSB Foundation in 2019 and $500,000 in 2022 for staff scholarships; $100,000 to Stanford University in 2022 for the Robert Duggan Microbiome Fund; and contributions to schools such as $400,000 to Junipero Serra High School in 2022, $90,000 to Riviera Ridge School in 2022, and $50,040 to Manhattan College for scholarships in 2022.[](https://www.grantmakers.io/profiles/v0/822151899-robert-w-duggan-foundation) Health-related support includes $100,000 to the CLL Society in 2023 for chronic lymphocytic leukemia awareness and patient aid. Other disbursements encompass $50,000 to Los Padres Boys Scouts of America in 2019 and a substantial $5 million to the Arias Foundation for Peace and Human Progress in 2023 for Peace Museum development.[](https://www.grantmakers.io/profiles/v0/822151899-robert-w-duggan-foundation)\n\nReligious contributions form a notable portion of grants, such as multiple donations to the Church of Scientology International ($200,000 in 2022, $200,000 in 2020, $50,000 in 2019) and $50,000 to the United States IAS Members' Trust in 2020.[](https://www.grantmakers.io/profiles/v0/822151899-robert-w-duggan-foundation) These activities reflect a targeted approach, with three grants reported in 2023 and varying numbers in prior years, often prioritizing California-based recipients alongside select international efforts. The foundation maintains no employees and files annually with the IRS, adhering to private foundation distribution requirements.[](https://projects.propublica.org/nonprofits/organizations/822151899)\n\n## Political Engagement\n\n### Advocacy for Free-Market Policies\n\nIn the mid-1990s, Duggan co-founded Metropolis Media with his son Demian to facilitate the transition of formerly communist countries, such as Croatia, Macedonia, Slovenia, and Serbia, toward free-market capitalism by establishing outdoor advertising networks that enabled consumer product promotion in emerging market economies.[](https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1) The initiative began with a $3 million investment and expanded to over 10,000 billboards in strategic urban locations, allowing approximately 10,000 small businesses to advertise and scale operations previously constrained by central planning.[](https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1) As chairman of the board, Duggan secured a seven-figure line of credit from Bank of America, reflecting early financial viability, and the company was later sold to Capital Research for over $45 million before being acquired by the French advertising firm JCDecaux.[](https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1)[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)\n\nThis venture exemplified Duggan's practical advocacy for free-market principles through infrastructure that fostered competition and consumer-driven growth in post-communist regions, contrasting with state-controlled media environments that had suppressed private enterprise.[](https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1) By prioritizing advertising as a tool for economic liberalization, Metropolis Media directly supported the shift from command economies to ones reliant on voluntary exchange and innovation, aligning with Duggan's broader entrepreneurial emphasis on enabling market participation for mutual benefit.[](https://www.linkedin.com/in/robertwduggan)\n\n### Financial Support for Conservative Candidates\n\nRobert Duggan has directed significant financial resources toward Republican causes, with a focus on supporting Donald Trump's 2020 presidential campaign through joint fundraising committees aligned with conservative priorities such as deregulation and free-market policies. In August 2020, Duggan contributed $200,000 to a committee benefiting Trump and the Republican National Committee (RNC).[](https://www.forbes.com/sites/michelatindera/2020/12/09/trump-picked-up-six-figure-checks-from-these-billionaires-in-the-days-before-and-after-the-election/) Between October 15 and November 23, 2020, he donated an additional $617,800 to the Trump Victory joint fundraising committee, which funneled funds to Trump's campaign, the RNC, and affiliated state parties.[](https://www.forbes.com/sites/michelatindera/2020/12/09/trump-picked-up-six-figure-checks-from-these-billionaires-in-the-days-before-and-after-the-election/)\n\nOverall, Duggan's contributions to the Trump Victory Fund totaled $1,638,200 during the 2020 cycle, reflecting his stated intent to increase support as the election approached.[](https://www.commondreams.org/views/2021/01/11/trumps-top-ten-billionaire-enablers) In the campaign's final weeks, he provided another $1 million to the same entity, part of a broader $4.6 million in donations to Trump-aligned groups.[](https://www.forbes.com/sites/michelatindera/2020/12/09/trump-picked-up-six-figure-checks-from-these-billionaires-in-the-days-before-and-after-the-election/) These efforts positioned Duggan among high-profile biotech investors backing Republican nominees, though public records show limited direct contributions to other individual conservative candidates beyond Trump.[](https://www.opensecrets.org/donor-lookup/results?name=robert+duggan)\n\nEarlier, on October 4, 2018, Duggan gave $4 million to the Florida Republican Party, a state-level organization that supports GOP candidates emphasizing limited government intervention.[](https://www.opensecrets.org/donor-lookup/results?cand=\u0026cycle=\u0026employ=\u0026order=desc\u0026page=2\u0026sort=A\u0026state=FL\u0026zip=\u0026name=duggan) Federal Election Commission filings confirm these transactions originated from Duggan's Clearwater, Florida, address, consistent with his residency and business interests. No verified records indicate substantial support for non-Republican or progressive candidates, aligning his giving with conservative electoral efforts.\n\n## Controversies and Criticisms\n\n### Corporate Governance Disputes\n\nIn 2015, following the announcement of Pharmacyclics' $21 billion acquisition by AbbVie, multiple shareholder class action lawsuits were filed against the company's board of directors, including CEO and Chairman Robert Duggan, alleging breaches of fiduciary duties in the sale process.[](https://www.pharmacyclicsshareholderlitigation.com/)[](https://www.sec.gov/Archives/edgar/data/1551152/000104746915002576/a2223854zs-4.htm) The suits, such as *Evangelista v. Duggan et al.* (filed March 13, 2015, in Santa Clara County Superior Court), claimed the board failed to adequately disclose material information and did not maximize shareholder value amid competing bids from Johnson \u0026 Johnson and others.[](https://www.casemine.com/judgement/us/5e4b97594653d04a457f636d)[](https://www.pharmacyclicsshareholderlitigation.com/media/486989/v1_pcy_amendednotice_041916_final.pdf) The litigation consolidated into *In re Pharmacyclics, Inc. Shareholder Litigation*, resulting in a disclosure-only settlement in 2016, where additional details on the auction process and financial projections were provided to shareholders without any admission of liability; the court approved the settlement, dismissing the case.[](https://www.pharmacyclicsshareholderlitigation.com/)[](https://www.leagle.com/decision/incaco20200214071)\n\nMore recently, at Summit Therapeutics, where Duggan serves as Chairman and CEO, a lawsuit filed in early 2025 accused him of self-dealing through a $520 million bridge loan arranged in 2024.[](https://news.bloomberglaw.com/esg/summit-ceo-bob-duggan-sued-over-outlandish-self-dealing-loan) The complaint alleged the loan terms were usurious and timed to exploit a dip in Summit's stock price before a licensing deal with Akeso Inc., allowing Duggan and his wife, co-CEO Mahkam Zanganeh, to extract approximately $114 million in personal benefits while the company faced liquidity pressures.[](https://news.bloomberglaw.com/esg/summit-ceo-bob-duggan-sued-over-outlandish-self-dealing-loan) This action highlighted governance concerns over Duggan's dominant control, as he and Zanganeh hold significant influence without independent board oversight mitigating conflicts of interest; the case remains ongoing as of October 2025.[](https://news.bloomberglaw.com/esg/summit-ceo-bob-duggan-sued-over-outlandish-self-dealing-loan)[](https://scientologymoneyproject.com/2025/06/05/bob-duggans-pharma-company-summit-therapeutics-targeted-by-powerhouse-securities-law-firm-pomerantz-llp/)\n\nSeparately, law firms including Pomerantz LLP and Bronstein, Gewirtz \u0026 Grossman have launched investigations into Summit for potential securities fraud related to disclosures on clinical trial outcomes and financial maneuvers, potentially implicating board governance failures in transparency and investor protections.[](https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc---smmt-302587123.html)[](https://www.wjbf.com/business/press-releases/accesswire/1071260/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-summit-therapeutics-inc-smmt-and-encourages-shareholders-to-learn-more-about-the-investigation) These probes, initiated in mid-2025, stem from claims that Summit and its executives issued misleading statements, though no formal class actions have been certified to date.[](https://www.cbs42.com/business/press-releases/accesswire/1087415/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc-smmt)\n\n### Public Scrutiny of Religious Ties\n\nDuggan has been a longtime member of the Church of Scientology, an organization he joined decades ago and to which he has donated nearly $360 million over his lifetime, making him its largest known contributor.[](https://www.forbes.com/profile/robert-duggan/)[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/) These contributions, confirmed by Duggan himself in a 2019 telephone interview with the *Tampa Bay Times*, occurred alongside his leadership of Pharmacyclics, which sold for $21 billion in 2015.[](https://www.sfgate.com/business/article/Robert-Duggan-Scientology-s-biggest-donor-4234071.php)[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/)\n\nPublic attention to Duggan's religious ties intensified following Pharmacyclics' success with Imbruvica, a cancer drug, positioning him as the world's wealthiest Scientologist.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp) Media profiles, including those in *Forbes* and *STAT News*, have highlighted his ongoing practice of Scientology, noting in a 2024 interview that he regularly reads works by founder L. Ron Hubbard.[](https://www.forbes.com/sites/leahrosenbaum/2020/10/01/the-scientologist-billionaire-trying-to-make-a-new-antibiotic/)[](https://www.statnews.com/2024/09/09/summit-therapeutics-lung-cancer-treatment-keytruda-robert-duggan/) Speculation arose in 2019 among Scientology observers that Duggan might have disaffiliated after such extensive giving, but he directly refuted this, affirming his dedication.[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/)\n\nScrutiny has centered on potential influences of Scientology on Duggan's business practices, with some reports questioning whether principles from the church shaped management at Pharmacyclics.[](https://www.science.org/content/blog-post/one-and-done) For instance, Duggan arranged for employees to pursue self-directed programs aimed at developing \"24 genius traits,\" a concept aligned with Hubbard's teachings on personal improvement, raising implicit concerns in biotech commentary about the rationality of such approaches amid high-stakes drug development.[](https://www.science.org/content/blog-post/geniuses-pharmacyclics) However, Duggan has attributed aspects of his success, including disciplined focus and ethical decision-making, to insights gained from Scientology, without evidence of direct operational interference or regulatory issues stemming from his faith.[](https://www.statnews.com/2024/09/09/summit-therapeutics-lung-cancer-treatment-keytruda-robert-duggan/)[](https://www.forbes.com/sites/matthewherper/2014/04/16/a-lucky-drug-made-pharmacyclics-robert-duggan-a-billionaire-will-long-term-success-follow/) No formal investigations or lawsuits have linked his religious ties to corporate misconduct, though the church's broader reputation for aggressive tactics and financial demands has colored perceptions of his philanthropy.[](https://nonprofitquarterly.org/philanthropy/21801-no-mystery-in-the-why-of-scientology-s-largest-donor.html)\n\n## Personal Life\n\n### Family Dynamics\n\nRobert Duggan met his future wife, Patricia \"Trish\" Hagerty, in the 1960s while both were students at the University of California, Santa Barbara, where they became involved in Scientology during the 1970s.[](https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/) The couple together raised eight children, including six adopted after the death of one son from brain cancer at age 26, an event that profoundly influenced Duggan's subsequent focus on oncology investments.[](https://www.forbes.com/profile/robert-duggan/)[](https://www.imaginemuseum.com/trish-duggan-talks-imagine-museum/)\n\nThe Duggans' family life centered on shared commitments to Scientology, with the couple and their children donating over $7.5 million to the Church of Scientology by 2008, earning recognition for their contributions.[](https://www.bloomberg.com/news/articles/2013-01-29/scientology-donor-becomes-a-billionaire-with-cancer-drug) They adopted multiple children, emphasizing family expansion through international adoptions, as Hagerty later reflected on the opportunities available in America for such placements.[](https://www.imaginemuseum.com/trish-duggan-talks-imagine-museum/) The marriage ended in divorce in 2017, after which Duggan maintained involvement in his children's lives amid his continued business pursuits.[](https://mabumbe.com/people/robert-duggan-biography-career-relationships-achievements-facts/)\n\n### Lifestyle and Personal Habits\n\n![Bob Duggan with his mountain bike in Costa Rica.](./_assets_/Bob_Duggan_with_bicycle.jpg)\nRobert Duggan maintains an active outdoor lifestyle centered on surfing, which he has pursued since his youth in Santa Cruz, California. He frequently travels to international surf destinations including Hawaii, Costa Rica, Nicaragua, and Mexico, often incorporating these trips into family activities by teaching his children the sport from as young as age three.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)[](https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/)\n\nAt age 80, Duggan continues to surf regularly, viewing each wave as a unique \"work of art\" that mirrors life's challenges and opportunities. He owns a vacation home on the west coast of Costa Rica, where he engages in surfing and other outdoor pursuits such as mountain biking.[](https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/)[](https://www.forbes.com/sites/leahrosenbaum/2020/10/01/the-scientologist-billionaire-trying-to-make-a-new-antibiotic/)\n\nDuggan's habits reflect a commitment to physical fitness and adventure, extending beyond surfing to include past achievements like completing the Palo Alto Marathon in 2 hours and 49 minutes. His approach emphasizes resilience and learning from experiences, akin to navigating ocean waves.[](https://tonyortega.org/2014/10/15/a-perplexing-tale-about-bob-duggan-the-richest-scientologist-in-the-world/)\n\n## Wealth Accumulation and Recognition\n\n### Net Worth Milestones\n\nDuggan achieved billionaire status in 2013 through the commercial success of Imbruvica (ibrutinib), Pharmacyclics' FDA-approved treatment for chronic lymphocytic leukemia, which drove substantial appreciation in the company's stock and his ownership stake exceeding 20%.[](https://www.forbes.com/profile/robert-duggan/)[](https://www.forbes.com/sites/matthewherper/2014/04/16/a-lucky-drug-made-pharmacyclics-robert-duggan-a-billionaire-will-long-term-success-follow/)\n\nThe most significant early wealth milestone occurred on May 21, 2015, when AbbVie completed its $21 billion acquisition of Pharmacyclics at $261.25 per share, yielding Duggan approximately $3.5 billion as the largest shareholder.[](https://www.fiercepharma.com/m-a/abbvie-s-21b-buyout-puts-pharmacyclics-execs-line-for-4b-payoff)[](https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/) This transaction marked one of the largest individual payouts from a public company buyout in biotech history, elevating his net worth to around $3 billion at the time.[](https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp)\n\nDuggan's subsequent net worth growth stemmed from venture investments, particularly his role as co-CEO and major stakeholder in Summit Therapeutics. The company's shares rose over 1,100% in 2024 following positive phase 3 trial data for ivonescimab, a PD-1/VEGF bispecific antibody in collaboration with Akeso, tripling Duggan's fortune to approximately $16 billion by September 2024.[](https://www.businessinsider.com/bob-duggan-summit-therapeutics-stock-wealth-billionaires-rich-list-biotech-2024-9)[](https://www.wsj.com/tech/biotech/how-a-surfer-who-never-finished-college-became-a-biotech-billionaire-c71eb75f)\n\n| Year | Event | Wealth Impact |\n|------|--------|---------------|\n| 2013 | Imbruvica FDA approval and sales ramp-up | Entered Forbes billionaire list; stake value surges with Pharmacyclics market cap exceeding $10 billion[](https://www.forbes.com/profile/robert-duggan/) |\n| 2015 | Pharmacyclics acquisition by AbbVie | $3.5 billion personal proceeds; net worth ~$3 billion post-sale[](https://www.fiercepharma.com/m-a/abbvie-s-21b-buyout-puts-pharmacyclics-execs-line-for-4b-payoff)[](https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/) |\n| 2024 | Summit Therapeutics stock surge on ivonescimab data | Net worth triples to ~$16 billion from holdings[](https://www.businessinsider.com/bob-duggan-summit-therapeutics-stock-wealth-billionaires-rich-list-biotech-2024-9)[](https://www.wsj.com/tech/biotech/how-a-surfer-who-never-finished-college-became-a-biotech-billionaire-c71eb75f) |\n\n### Awards and Industry Acknowledgments\n\nIn 1985, Robert Duggan received the United States Congressional Medal of Merit from Texas Congressman Ron Paul, recognizing his early contributions to venture investing and technology development.[](https://investors.pulsebiosciences.com/board-member/robert-bob-duggan)[](https://www.lmc-clients.com/duggan/beta/about/)\n\nIn 2000, French President Jacques Chirac awarded Duggan the Knight of the Legion of Honor for his leadership in advancing robotic surgical technology as CEO of Computer Motion, Inc., which facilitated innovations in minimally invasive procedures prior to its acquisition by Intuitive Surgical.[](https://www.smmttx.com/our-company/leadership/bob-duggan-2/)[](https://www.lmc-clients.com/duggan/beta/about/)[](https://investors.pulsebiosciences.com/board-member/robert-bob-duggan)\n\nDuggan was nominated as a finalist for the Ernst \u0026 Young Entrepreneur of the Year Award in Northern California in 2012, in acknowledgment of his role in revitalizing Pharmacyclics, Inc., where he served as CEO and chairman during a period of significant revenue growth exceeding 61% year-over-year among nominees.[](https://www.globenewswire.com/news-release/2012/05/15/1186731/0/en/Ernst-Young-Entrepreneur-Of-The-Year-R-2012-Award-Nominees-in-Northern-California-Experience-61-Percent-Increase-in-Year-Over-Year-Revenue-Growth.html)\n\nIn 2016, the University of California, Santa Barbara's College of Engineering presented Duggan with the Venky Narayanamurti Entrepreneurial Leadership Award, honoring his visionary investments and executive achievements in biotechnology and medical technology as a UCSB alumnus and philanthropist.[](https://engineering.ucsb.edu/news/alum-robert-duggan-receives-narayanamurti-entrepreneurial-leadership-award)[](https://www.noozhawk.com/ucsb_alum_robert_duggan_receives_2016_venky_narayanamurti_entrepreneurial_l/)"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761882129363,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Robert Duggan - Forbes\",\"description\":\"In 2020, Robert Duggan invested $63 million in Nasdaq-listed Summit Therapeutics and became its Co-CEO, leading the biotech in developing targeted oncologyÂ ...\",\"url\":\"https://www.forbes.com/profile/robert-duggan/\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"How Robert Duggan Became a Billionaire - Investopedia\",\"description\":\"Robert Duggan has found success as an entrepreneur and investor in baking, robotics, and, most recently, biotechnology. Â· Duggan grew up in northern CaliforniaÂ ...\",\"url\":\"https://www.investopedia.com/articles/investing/122815/how-robert-duggan-became-billionaire.asp\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"AbbVie's $21B buyout puts Pharmacyclics execs in line for $4B payoff\",\"description\":\"Mar 24, 2015 Â· Pharmacyclics CEO Robert Duggan would add $3.5 billion to his already substantial wealth, if and when AbbVie's ($ABBV) $21 billion buyoutÂ ...\",\"url\":\"https://www.fiercepharma.com/m-a/abbvie-s-21b-buyout-puts-pharmacyclics-execs-line-for-4b-payoff\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Robert Duggan wins again as Summit lung cancer ... - STAT News\",\"description\":\"Sep 9, 2024 Â· In his book, Vardi says that Duggan invested about $50 million of his own money in Pharmacyclics. The sale of the company to AbbVie netted himÂ ...\",\"url\":\"https://www.statnews.com/2024/09/09/summit-therapeutics-lung-cancer-treatment-keytruda-robert-duggan/\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Robert (Bob) Duggan | Board Member - Pulse Biosciences Inc.\",\"description\":\"Duggan has been CEO of Duggan Investments, a venture capital and public equity investment firm. His venture investments primarily focus on patient-friendlyÂ ...\",\"url\":\"https://investors.pulsebiosciences.com/board-member/robert-bob-duggan\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Bob Duggan - Summit Therapeutics\",\"description\":\"Duggan was Chairman, CEO, and the largest investor in Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-moleculeÂ ...\",\"url\":\"https://www.smmttx.com/our-company/leadership/bob-duggan-2/\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Robert Duggan Biography: Career, Relationships, Achievements ...\",\"description\":\"Jan 27, 2025 Â· Robert Duggan was born in 1944 in Oakland, California, as the third of five children to an Irish immigrant father who worked as an industrialÂ ...\u003c|separator|\u003e\",\"url\":\"https://mabumbe.com/people/robert-duggan-biography-career-relationships-achievements-facts/\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Bay Area surfer, Scientologist and billionaire is tackling one of ...\",\"description\":\"Oct 1, 2024 Â· Bob Duggan would have another multibillion-dollar product. For now, his fortunes are focused on an experimental cancer drug that wowed researchers.\",\"url\":\"https://www.siliconvalley.com/2024/09/30/biotechs-unlikely-david-vs-goliath-surfer-scientologist-and-savvy-businessman-becomes-a-billionaire/\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"About Bob - Bob Duggan\",\"description\":\"The son of a well-educated European immigrant industrial engineer father and University of Nebraska graduate nurse mother, Bob learned the value of hard workÂ ...Missing:  biography | Show results with:biography\",\"url\":\"https://www.lmc-clients.com/duggan/beta/about/\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Robert Duggan Biography - Brooksy Society\",\"description\":\"Jun 27, 2020 Â· Robert Duggan was born in Berkely, CA during the mid-1940s. His father, who immigrated to the United States from Ireland,Â ...\",\"url\":\"https://brooksysociety.com/robert-duggan-biography/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Bob Duggan - Bloomberg Billionaires Index\",\"description\":\"Duggan is an investor who acquires and sells companies in diverse sectors including robotic surgery and billboards. He sold drugmaker Pharmacyclics in 2015.\u003c|separator|\u003e\",\"url\":\"https://www.bloomberg.com/billionaires/profiles/robert-w-duggan/\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Bob Duggan - Chief Executive Officer \u0026 Chairman of the Board at ...\",\"description\":\"My venture investments focus on developing patient-friendly, breakthrough solutions to complex diseases. With every endeavor, I strive to create meaningful andÂ ...\",\"url\":\"https://www.linkedin.com/in/robertwduggan\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"A surfer without a degree is worth $16 billion after his biotech ...\",\"description\":\"Sep 26, 2024 Â· Duggan opened a bakery called Cookie Muncher's Paradise in 1976 with the help of his then-brother-in-law. They converted it into a luxuryÂ ...\",\"url\":\"https://www.businessinsider.com/bob-duggan-summit-therapeutics-stock-wealth-billionaires-rich-list-biotech-2024-9\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Bob Duggan â€” geniusinc\",\"description\":\"Bob Duggan's Ventures include: Â· Paradise Bakery (1976-1987): Bob's startup investment helped Paradise Bakery grow before its acquisition in 1987. Â· GovernmentÂ ...Missing:  early | Show results with:early\",\"url\":\"https://www.geniusinc.com/aboutbobduggan\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Robotic-assisted surgery (RAS) â€” Duggan Investments Research\",\"description\":\"Robotic-Assisted Surgery (RAS) devices enable surgeons to use computers and installed software to control and move surgical instruments through one or moreÂ ...Missing:  Robert | Show results with:Robert\",\"url\":\"https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1-1\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"General 1 â€” Duggan Investments Research\",\"description\":\"Bob is a high-tech entrepreneur. He is very proud to have worked with exceptional men and women in medicine and technology.\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.dugganinvestmentsresearch.com/about-bob-duggan\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"Duggan Investments Research\",\"description\":\"Duggan Investments' current projects are focused on cutting-edge biosciences. These include groundbreaking developments in cancer treatment, anti-microbialÂ ...About Bob Duggan Â· Projects Â· About Our Team Â· Media\",\"url\":\"https://www.dugganinvestmentsresearch.com/\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"Board of Directors - Pulse Biosciences Inc.\",\"description\":\"From 2008 to 2015, Mr. Duggan was Chairman, CEO and the largest investor in Pharmacyclics, a patient-friendly, science-based, employee-driven developer of smallÂ ...\",\"url\":\"https://investors.pulsebiosciences.com/corporate-governance/board-of-directors\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Robert W. Duggan - Summit Therapeutics\",\"description\":\"Mr. Duggan led both the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICAÂ®) with Johnson \u0026 Johnson in 2011, and theÂ ...\",\"url\":\"https://www.smmttx.com/our-company/board-of-directors-2/robert-w-duggan/\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.wsj.com/tech/biotech/how-a-surfer-who-never-finished-college-became-a-biotech-billionaire-c71eb75f\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Duggan Robert W Portfolio Holdings - Fintel\",\"description\":\"Insider Profile, DUGGAN ROBERT W. Portfolio Value, $ 855,329,633. Current Positions, 1. Activist Positions, 1. Latest Holdings, Performance, AUM (from 13F,Â ...Missing:  tech | Show results with:tech\",\"url\":\"https://fintel.io/i/duggan-robert-w\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"Robert Duggan: Positions, Relations and Network - MarketScreener\",\"description\":\"Known holdings in public companies ; SUMMIT THERAPEUTICS INC. 75.38%. 2025-09-10, 556,093,090 ( 75.38% ), 13 179 M $, 2025-08-30 ; PULSE BIOSCIENCES, INC. 79.31%.\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.marketscreener.com/insider/ROBERT-DUGGAN-A0089M/\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"DUGGAN ROBERT W Top 13F Holdings - WhaleWisdom.com\",\"description\":\"Detailed Profile of DUGGAN ROBERT W portfolio of holdings. SEC Filings include 13F quarterly reports, 13D/G events and more.Missing:  ongoing portfolio companies\",\"url\":\"https://whalewisdom.com/filer/duggan-robert-w\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Robert W Duggan Net Worth (2025) - GuruFocus\",\"description\":\"Robert W Duggan owns 43,290,683 shares of Pulse Biosciences Inc (PLSE) as of December 13, 2024, with a value of $753 Million and a weighting of 6.21%. Robert WÂ ...Missing:  ongoing | Show results with:ongoing\",\"url\":\"https://www.gurufocus.com/insider/3472/robert-w-duggan\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"Robert Duggan investment portfolio | PitchBook\",\"description\":\"Robert Duggan has made numerous investments in companies like Subskribe, CASI Pharmaceuticals, and Genoscience Pharma within the Business/Productivity SoftwareÂ ...\",\"url\":\"https://pitchbook.com/profiles/investor/110114-11\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"Robert W. Duggan, CFA - Axonic Capital\",\"description\":\"Mr. Duggan is a Managing Director at Axonic Capital working in the Business Development Group. Prior to Axonic, he was a Partner and Senior Portfolio ManagerÂ ...\",\"url\":\"https://www.axoniccap.com/team/robert-duggan/\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"Domination of the market with over 80% market share\",\"description\":\"In 1975 he invested 50% of the company's venture capital for 50% of the equity and a seat on the board. In his new role, Duggan provided sound financial andÂ ...\",\"url\":\"https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1-1-1-1-1\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"This Legendary Billionaire Biotech Investor Has Remained ... - Forbes\",\"description\":\"Jan 13, 2023 Â· The untold story of Wayne Rothbaum and the worst trade of his life. But what cost him some $700 million turned out to be the boon for countless cancer patients.\",\"url\":\"https://www.forbes.com/sites/nathanvardi/2023/01/13/for-blood-and-money-book-excerpt-wayne-rothbaum-pharmacyclics-robert-duggan/\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.quiverquant.com/news/Insider%2BPurchase%253A%2BCo-Chief%2BExecutive%2BOfficer%2Bof%2B%2524SMMT%2BBuys%2B26%252C680%2BShares\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Top Key Executive Robert Duggan, Pulse Biosciences, Inc.'s ...\",\"description\":\"Dec 12, 2024 Â· In Pulse Biosciences' case, its Top Key Executive, Robert Duggan, is the largest shareholder, holding 69% of shares outstanding. In comparison,Â ...\",\"url\":\"https://finance.yahoo.com/news/top-key-executive-robert-duggan-124819517.html\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"The man who gave Scientology $360 million actually answered the ...\",\"description\":\"Nov 22, 2019 Â· Scientology watchers suspected Bob Duggan, a venture capitalist, might have left the organization after four decades of dedication andÂ ...\",\"url\":\"https://www.tampabay.com/news/business/2019/11/22/the-man-who-gave-scientology-360-million-actually-answered-the-phone/\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Scientology Donor Becomes a Billionaire With Cancer Drug\",\"description\":\"Jan 29, 2013 Â· One big recipient of Duggan's giving is the Church of Scientology. The billionaire is the church's largest financial supporter, according toÂ ...Missing:  venture | Show results with:venture\",\"url\":\"https://www.bloomberg.com/news/articles/2013-01-29/scientology-donor-becomes-a-billionaire-with-cancer-drug\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Robert Duggan Scientology's biggest donor - SFGATE\",\"description\":\"Jan 29, 2013 Â· \\\"He is in a category of his own, having donated more than $20 million. Nobody else even comes close to having donated that much.\\\"Missing:  contributions | Show results with:contributions\",\"url\":\"https://www.sfgate.com/business/article/Robert-Duggan-Scientology-s-biggest-donor-4234071.php\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Bob Duggan - Public nonprofit investment\",\"description\":\"He has donated hundreds of millions of dollars to various non-profit organizations, served on the board of trustees since 1989 at his alma mater, the UniversityÂ ...Missing:  Robert education\",\"url\":\"https://www.lmc-clients.com/duggan/beta/philanthropist/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Robert W Duggan Foundation - Nonprofit Explorer - ProPublica\",\"description\":\"Designated as a 501(c)(3) Organizations for any of the following purposes: religious, educational, charitable, scientific, literary, testing for publicÂ ...\u003c|separator|\u003e\",\"url\":\"https://projects.propublica.org/nonprofits/organizations/822151899\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Robert W Duggan Foundation - Grantmakers.io\",\"description\":\"Profile for Robert W Duggan Foundation (Miami, FL - EIN 822151899) including grantees and board members as of 2023 tax year.\",\"url\":\"https://www.grantmakers.io/profiles/v0/822151899-robert-w-duggan-foundation\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"Helping countries transition to free-market capitalism\",\"description\":\"Metropolis Media was formed by Robert Duggan in the mid-1990s to help people and companies in formerly communist countries transition to free-market capitalism.Missing:  venture advocacy policies\",\"url\":\"https://www.dugganinvestmentsresearch.com/new-page-1-1-1-1-1\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Trump Picked Up Six-Figure Checks From These Billionaires In The ...\",\"description\":\"Dec 9, 2020 Â· According to federal filings, Duggan gave another $4.6 million to groups supporting Trump in the waning days of the 2020 presidential campaign.Missing:  political | Show results with:political\",\"url\":\"https://www.forbes.com/sites/michelatindera/2020/12/09/trump-picked-up-six-figure-checks-from-these-billionaires-in-the-days-before-and-after-the-election/\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Trump's Top Ten Billionaire Enablers - Common Dreams\",\"description\":\"Jan 11, 2021 Â· Biotech investor Robert Duggan, worth $2.6 billion, donated $1,638,200 to the Trump Victory Fund. In the final days of the campaign, DugganÂ ...\",\"url\":\"https://www.commondreams.org/views/2021/01/11/trumps-top-ten-billionaire-enablers\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.opensecrets.org/donor-lookup/results?name=robert+duggan\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.opensecrets.org/donor-lookup/results?cand=\u0026cycle=\u0026employ=\u0026order=desc\u0026page=2\u0026sort=A\u0026state=FL\u0026zip=\u0026name=duggan\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Pharmacyclics Shareholder Litigation\",\"description\":\"Beginning on March 13, 2015, the following class action lawsuits: Evangelista v. Duggan, et al., No. 1-15-CV-278055 (the â€œEvangelista Actionâ€); Treppel v.Missing:  details | Show results with:details\",\"url\":\"https://www.pharmacyclicsshareholderlitigation.com/\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"AbbVie Inc. - SEC.gov\",\"description\":\"Litigation. On March 13, 2015, a putative class action lawsuit, Evangelista v. Duggan et al, was filed against Pharmacyclics, the members of the PharmacyclicsÂ ...\",\"url\":\"https://www.sec.gov/Archives/edgar/data/1551152/000104746915002576/a2223854zs-4.htm\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"Evangelista v. Duggan | H044087 | Cal. Ct. App. | Judgment | Law ...\",\"description\":\"Based on the investigation, Plaintiffs each filed a class action lawsuit against Pharmacyclics, its board of directors, and AbbVie (collectively Defendants);Â ...\u003c|separator|\u003e\",\"url\":\"https://www.casemine.com/judgement/us/5e4b97594653d04a457f636d\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"[PDF] superior court of the state of california\",\"description\":\"Jan 19, 2016 Â· 1 These Actions were brought on behalf of classes of stockholders of Pharmacyclics, Inc. against the Company, the members of its Board ofÂ ...\",\"url\":\"https://www.pharmacyclicsshareholderlitigation.com/media/486989/v1_pcy_amendednotice_041916_final.pdf\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"EVANGELISTA v. DUGGAN | No. H044087... | 20200214071 - Leagle\",\"description\":\"Feb 14, 2020 Â· EVANGELISTA v. DUGGAN. EVANGELISTA v. DUGGAN. No. H044087. View Case ... Click on the case name to see the full text of the citing case.Missing:  Pharmacyclics details\",\"url\":\"https://www.leagle.com/decision/incaco20200214071\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Summit CEO Bob Duggan Sued Over 'Outlandish' Self-Dealing Loan\",\"description\":\"Mar 24, 2025 Â· CEO Bob Duggan forced the biotech company into a â€œplainly usuriousâ€ $520 million loan that let the billionaire and his wife squeeze $114Â ...Missing:  disputes | Show results with:disputes\",\"url\":\"https://news.bloomberglaw.com/esg/summit-ceo-bob-duggan-sued-over-outlandish-self-dealing-loan\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Bob Duggan's Pharma Company Summit Therapeutics Targeted by ...\",\"description\":\"Jun 5, 2025 Â· Scientology billionaire Bob Duggan and his wife and co-CEO Maky Zanganeh of Summit Therapeutics (SMMT) have been targeted for a possible class action lawsuit.\",\"url\":\"https://scientologymoneyproject.com/2025/06/05/bob-duggans-pharma-company-summit-therapeutics-targeted-by-powerhouse-securities-law-firm-pomerantz-llp/\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On ...\",\"description\":\"Oct 18, 2025 Â· The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawfulÂ ...\",\"url\":\"https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc---smmt-302587123.html\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Bronstein, Gewirtz \u0026 Grossman, LLC Announces an Investigation ...\",\"description\":\"Sep 19, 2025 Â· Bronstein, Gewirtz \u0026 Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Shareholders to Learn MoreÂ ...\",\"url\":\"https://www.wjbf.com/business/press-releases/accesswire/1071260/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-summit-therapeutics-inc-smmt-and-encourages-shareholders-to-learn-more-about-the-investigation\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On ...\",\"description\":\"Oct 17, 2025 Â· The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawfulÂ ...\",\"url\":\"https://www.cbs42.com/business/press-releases/accesswire/1087415/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-summit-therapeutics-inc-smmt\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"The Scientologist Billionaire Trying To Make A New Antibiotic - Forbes\",\"description\":\"Oct 1, 2020 Â· Bob Duggan could easily have called it a career in 2015, after he sold Pharma- cyclics, his cancer-drug biotech, to AbbVie.Missing:  beginnings | Show results with:beginnings\",\"url\":\"https://www.forbes.com/sites/leahrosenbaum/2020/10/01/the-scientologist-billionaire-trying-to-make-a-new-antibiotic/\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"One and Done | Science | AAAS\",\"description\":\"Matthew Herper has a good piece in Forbes on Robert Duggan and Pharmacyclics. In the course of it, we learn this interesting (and perhaps disturbing) bit ofÂ ...\",\"url\":\"https://www.science.org/content/blog-post/one-and-done\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Geniuses at Pharmacyclics | Science | AAAS\",\"description\":\"CEO Bob Duggan is apparently encouraging the staff there to take a course in how to \\\"become geniuses\\\". Duggan, 70, believes so deeply in Barrios' researchÂ ...Missing:  Robert | Show results with:Robert\",\"url\":\"https://www.science.org/content/blog-post/geniuses-pharmacyclics\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire ...\",\"description\":\"Apr 17, 2014 Â· A combination of management smarts, providence and a breakthrough treatment made Robert Duggan a biotech billionaire. Long-term success?\",\"url\":\"https://www.forbes.com/sites/matthewherper/2014/04/16/a-lucky-drug-made-pharmacyclics-robert-duggan-a-billionaire-will-long-term-success-follow/\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"No Mystery in the â€œWhyâ€ of Scientology's Largest Donor\",\"description\":\"Feb 14, 2013 Â· It's only purpose is to steal investor monies and give it to criminal David Miscavige. Robert Duggan was Reed Slatkins mentor, if you areÂ ...\",\"url\":\"https://nonprofitquarterly.org/philanthropy/21801-no-mystery-in-the-why-of-scientology-s-largest-donor.html\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Trish Duggan talks Imagine Museum\",\"description\":\"In 2015, Robert Duggan sold his company, Pharmacyclics, for $21 billion ... The Duggan family relocated to the Clearwater area a decade ago. The workÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.imaginemuseum.com/trish-duggan-talks-imagine-museum/\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"A perplexing tale about Bob Duggan, the richest Scientologist in the ...\",\"description\":\"Oct 15, 2014 Â· We have an unusual and, we must say, rather mystifying story to tell you today. It's about a successful businessman by the name of Robert W. Duggan.\",\"url\":\"https://tonyortega.org/2014/10/15/a-perplexing-tale-about-bob-duggan-the-richest-scientologist-in-the-world/\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Ernst \u0026 Young Entrepreneur Of The Year(R) 2012 Award\",\"description\":\"May 15, 2012 Â· Ernst \u0026 Young Entrepreneur Of The Year(R) 2012 Award Nominees ... Robert Duggan, CEO \u0026 Chairman of the Board, Pharmacyclics, Inc. MikeÂ ...\",\"url\":\"https://www.globenewswire.com/news-release/2012/05/15/1186731/0/en/Ernst-Young-Entrepreneur-Of-The-Year-R-2012-Award-Nominees-in-Northern-California-Experience-61-Percent-Increase-in-Year-Over-Year-Revenue-Growth.html\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Alum Robert Duggan receives Narayanamurti Entrepreneurial ...\",\"description\":\"Mar 2, 2016 Â· Robert Duggan - philanthropist, venture capitalist and alumnus - was presented with the 2016 Narayanamurti Entrepreneurial Leadership Award.Missing:  education | Show results with:education\",\"url\":\"https://engineering.ucsb.edu/news/alum-robert-duggan-receives-narayanamurti-entrepreneurial-leadership-award\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"UCSB Alum Robert Duggan Receives 2016 Venky Narayanamurti ...\",\"description\":\"Mar 10, 2016 Â· To recognize him for his accomplishments and vision, Duggan was presented with the Venky Narayanamurti Entrepreneurial Leadership Award.\",\"url\":\"https://www.noozhawk.com/ucsb_alum_robert_duggan_receives_2016_venky_narayanamurti_entrepreneurial_l/\",\"favicon\":\"\"}],\"images\":[{\"id\":\"a1e2f150a84f\",\"caption\":\"Robert Duggan\",\"url\":\"./_assets_/Entrepreneur_-_Bob_Duggan.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"985c89ed0453\",\"caption\":\"Bob Duggan with his mountain bike in Costa Rica.\",\"url\":\"./_assets_/Bob_Duggan_with_bicycle.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Robert_Duggan_(venture_capitalist)\",\"title\":\"Robert Duggan (venture capitalist)\",\"content\":\"$1f\",\"description\":\"Robert Duggan (venture capitalist)\\n\\nRobert Duggan \\nRobert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and...\",\"metadata\":{\"categories\":[\"Bob Duggan\"],\"lastModified\":\"1761584819\",\"contentLength\":\"51533\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"27675\",\"recentViews\":\"27675\",\"dailyAvgViews\":922.5,\"qualityScore\":1,\"lastViewed\":\"1761882129\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761882129361,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Robert_Duggan_(venture_capitalist)\"],\"queryHash\":\"[\\\"page\\\",\\\"Robert_Duggan_(venture_capitalist)\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Robert Duggan (venture capitalist)\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Robert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and healthcare. He gained prominence as CEO of Pharmacyclics, Inc., where he invested personal funds to revive the struggling firm and oversaw the development of ibrutinib (Imbruvica), a breakthrough treatment for blood cancers that drove the company's $21 billion acquisition by AbbVie in 2015, yielding Duggan over $3.5 billion personally. Previously, Duggan chaired Computer Motion from 1990...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Bob Duggan\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Robert_Duggan_(venture_capitalist)\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Robert Duggan (venture capitalist)\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Robert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and healthcare. He gained prominence as CEO of Pharmacyclics, Inc., where he invested personal funds to revive the struggling firm and oversaw the development of ibrutinib (Imbruvica), a breakthrough treatment for blood cancers that drove the company's $21 billion acquisition by AbbVie in 2015, yielding Duggan over $3.5 billion personally. Previously, Duggan chaired Computer Motion from 1990...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Robert_Duggan_(venture_capitalist)\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Robert Duggan (venture capitalist)\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:44.819Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Robert Duggan (venture capitalist)\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Robert W. Duggan is an American billionaire entrepreneur and venture capitalist focused on biotechnology and healthcare. He gained prominence as CEO of Pharmacyclics, Inc., where he invested personal funds to revive the struggling firm and oversaw the development of ibrutinib (Imbruvica), a breakthrough treatment for blood cancers that drove the company's $21 billion acquisition by AbbVie in 2015, yielding Duggan over $3.5 billion personally. Previously, Duggan chaired Computer Motion from 1990...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="Njk0OWE5NTctNzQ4OC00NTdjLWFiZWYtNzdlNWU0ZWEzZDA0">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Robert_Duggan_(venture_capitalist)\"}]}]\n"])</script></body></html>